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ABSTRACT 
The hepatitis C virus (HCV) is the major cause of liver disease and it is estimated that 
around 170 millions of people are infected worldwide. The available therapy is a 
combination of pegylated-interferon-alpha, ribavirin and since 2011, also NS3/4A 
protease inhibitors boceprevir and telaprevir. The standard treatment is associated with 
considerable side effects and does not cure all patients. Several vaccine candidates, 
prophylactic and therapeutic, are in the developing phase, but none of them so far have 
proven to be able to prevent or clear the HCV infection. Thus there is a vital need for an 
alternative approach for chronically infected HCV patients who do not respond to the 
standard treatment. Chronic HCV infection leads to severe liver inflammation and 
subsequent cirrhosis and hepatocarcinoma. T cell failure has been indicated as the main 
reason of viral persistence. On the contrary, an efficient T cell response has been 
suggested to hold the key to HCV resolution. In particular, antiviral T cells that are 
polyfunctional are associated with effective control of HCV replication. The present 
thesis investigated two different approaches to generate HCV-specific polyfunctional T 
cells and their potential to reduce HCV RNA+ hepatoma cells and to reduce HCV 
antigen+ tumor growth was assessed subsequently. Here the two approaches are based 
on the idea on T cell receptor (TCR) transfer that enables introduction of HCV-antigen 
specificity from one T cell to another, and DNA vaccination that is enhanced by 
electroporation. Paper I and II demonstrated that HCV NS3 (NS31073-1081) and NS5A 
(NS5A1992-2000) -specific TCR isolated from HLA-A2 transgenic mice can be 
transferred to human T cells. Such HCV-specific redirected human T cells demonstrate 
a different mechanism of action associated with their antigen specificity. NS3-specific 
TCRs were polyfunctional with potent lytic activity capable to eliminate human 
hepatoma HCV replicon cells replicating HCV subgenomic RNA, whilst the NS5A-
specific TCRs instead ware mainly IFN-γ producers and less cytolytic. This has an 
interesting implication as the latter may spare the host from unwanted cell injury during 
elimination of HCV-infected cells. Paper III explored the potential of the NS5A DNA 
vaccine used in paper II. This pre-clinical study showed that one single injection of the 
vaccine followed by electroporation could give rise to a polyfunctional T cell response 
in both wild-type and NS5A-transgenic mice, thought the latter group showed signs of 
tolerance. A series of truncated NS5A vaccine constructs revealed the locations of the 
protective antigen that gives the protective immunity. In this study, new murine MHC-I 
restricted CTL epitope were also identified, which enables immunological studies in 
HCV transgenic mouse models. These findings provide evidence that high-magnitude 
and high-quality T cell response able to assist the immune control of HCV can be 
engineered in vitro and by therapeutic vaccination. It has implications for development 
of HCV treatments for patients who cannot be cured by antiviral therapy. The TCR-
reagents may also serve as tools to gain better understanding of HCV immunology.  
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THESIS SUMMARY  
 
The hepatitis C virus was identified in 1989 by Choo et al (Choo, Kuo et al. 1989) and 
it is one of the major causes of liver disease since it is estimated that around 170 
millions of people in the World are infected (Shepard, Finelli et al. 2005).The available 
therapy is a combination of pegylated-interferon-alpha, ribavirin and, since their 
introduction in 2011, also NS3/4A protease inhibitors boceprevir and telaprevir 
(Jacobson, McHutchison et al. 2011; Poordad and Khungar 2011). This treatment is 
long, expensive, it leads to several side effects and, most important of all, it does not 
have a 100% efficacy (Assis and Lim 2012). In particular there is still a group of 
patients, especially infected with HCV genotype 1, who do not respond to the standard 
treatment (Ghany, Nelson et al. 2011). Several vaccine candidates, prophylactic and 
therapeutic, are in the developing phase, but none of them so far demonstrated to be 
able to prevent or clear the HCV infection (Feinstone, Hu et al. 2012). Therefore the 
need of an alternative approach, in particular for those patients who do not respond to 
the standard treatment, is urgent. 
 
The problem with the HCV infection is the chronic persistence of the virus that leads to 
liver inflammation and subsequent cirrhosis and hepatocarcinoma (Seeff 2002). The 
main responsible for this failure in clearing the virus is the T cell disfunction that can 
be caused by several factors like exhaustion, viral escape etc (Thimme, Oldach et al. 
2001; Klenerman and Thimme 2012). An efficient T cell response seems to be the key 
for resolution of the HCV infection and several studies indicate that polyfunctional T 
cells are superior then monofunctional T cells secreting just one cytokine in fighting 
viral infection (Iyasere, Tilton et al. 2003; Younes, Yassine-Diab et al. 2003; Zimmerli, 
Harari et al. 2005; Ciuffreda, Comte et al. 2008).  
 
Therefore we decided to focus our research interest in the generation of polyfunctional 
T cells against HCV genotype 1 CTL epitopes (NS31073 and NS5A1992) associated with 
viral clearance (Lechner, Wong et al. 2000; Chang, Thimme et al. 2001; Urbani, Uggeri 
et al. 2001; Shoukry, Grakoui et al. 2003), Chang KM 2001, Urbani S 2001). We used 
two different approaches: TCR redirection (paper I and II) and DNA vaccination (paper 
III). 
 
We first generated T-BW cell hybrid clones specific for HCV NS31073 and NS5A1992 
(paper I). HLA-A2 transgenic mice (Pascolo, Bervas et al. 1997) were vaccinated with 
DNA plasmids encoding for NS3/4A and NS5A and electroporated to generate HCV-
specific CD8+ T cells. The CD8+ T cells from these mice were purified, stimulated 
with the selected peptides and fused with BW cells. The resulting T-BW hybrid clones 
were HAT-selected, the survivors were screened for surface CD3 expression and 
production of IL-2 and IFN-γ after stimulation with peptide loaded T2 cells. In Table 
S1 the screening process is summarized. 
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Table S1. Screening summary of T-BW cell hybrid clones. 
 
 
 
 
 
 
The T-BW hybrid clones were extensively characterized in terms of TCR avidity and 
affinity with the purpose of identifying the clone with the highest avidity for the 
specific HCV peptide. The final aim of this process is indeed the identification of TCR 
genes for TCR redirection of human T cells and it has been shown that high avidity 
TCR have a better antiviral action (Appay and Iglesias 2011). We chose to use murine 
TCRs because: 1) they have a higher surface expression in human cells compared to the 
endogenous TCR (Cohen, Zhao et al. 2006); 2) they do not pair with the human alpha 
and beta TCR chain to circumvent TCR mispairing that can lead to off target toxicity 
(Kieback and Uckert 2010); 3) clinical adoptive transfer studies with TCR redirected T 
cells expressing murine TCRs have already demonstrated that the immune response 
against these exogenous TCRs do not affect the outcome of the therapy (Davis, Theoret 
et al. 2010). 
 
As result of the screening process two TCR candidates for each HCV CTL peptide 
were chosen for the TCR redirection study (paper II). For NS31073 the clones H4 and F8 
demonstrated the highest avidity while clones 69 and 19 showed the highest avidity for 
NS5A1992 (in Table S2 the CDR3 loops from the TCRs chosen for the T cells 
redirection study are summarized). These TCR genes were codon optimized for 
expression in human cells and cloned into a retroviral vector. The MP71 vector was 
chosen because it is modified to guarantee higher transgene expression in T cells 
(Engels, Cam et al. 2003; Leisegang, Engels et al. 2008). The structure of the gene 
cassette was designed to ensure an even expression of alpha and beta TCR chains so the 
two genes were linked by the autoprotease 2A sequence in a single construct. Human 
PBL from healthy donor and HCV chronic patients were transduced by spinoculation 
and the TCR expression and functionality were evaluated by flow-cytometry and 
functional analyses. 
 
Table S2. CDR3 loops from alpha (A) and beta (B) chains of the TCRs selected for the 
T cell redirection study. 
 
    A)                                                       B) 
 
 
 
 
 
 
The most interesting finding was the correlation between the antigen specificity and the 
antiviral activity. We demonstrated that while NS3-specific T cells present a 
polyfunctional profile with a clear lytic activity against human hepatoma HCV replicon 
cells, NS5A-specific T cells mainly secrete IFN-γ and interfere with viral replication in 
HCV peptide 
specificity 
Total HAT+ 
clones 
Total CD3+ 
clones 
Stable IL-2+ and 
IFN-γ+ clones 
NS31073 108 95 9 
NS5A1992 103 87 7 
TCR ID CDR3 alpha chain 
H4 CAMREITGNTGKLIFGL 
F8 CAVSNMGYKLTFGT 
19 CAASLITGNTGKLIFGL 
69 CIVTDLGITGNTGKLIFGL 
TCR ID CDR3 beta chain 
H4 CASSDALGGEDAEQFFGPGTRL 
F8 CASSQEMGGALEQYFGPGTRL 
19 CASSLTANTEVFFGKGTRLT 
69 CASGDEGYNSPLYFAAGTRLT 
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a less effective manner and without lytic activity. Our result is in accordance with other 
studies were HCV replicon models were used to show that the non-cytolytic 
mechanism contributes to control HCV infection (Lohmann, Korner et al. 1999; Blight, 
Kolykhalov et al. 2000) and in particular IFN-γ is the main inhibitor of viral replication 
(Frese, Schwarzle et al. 2002; Jo, Aichele et al. 2009). In vivo studies conducted with 
chimpanzees also showed that viral clearance can occur in the absence of elevated 
alanine aminotransferase levels and with only minimal evidence of liver cell injury but 
with detectable IFN-γ messenger RNA in the liver (Bigger, Brasky et al. 2001; Su, 
Pezacki et al. 2002; Thimme, Bukh et al. 2002). Taken together these findings point out 
the possibility of eliminating HCV replication from infected cells without actual killing. 
This is particularly important for a possible therapeutic use of HCV redirected T cells 
in chronic patients who already suffer from a severe liver damage. This approach 
anyway would be intended as a complement to the antiviral therapy and moreover, the 
combined effect of NS3 and NS5A redirected T cells still needs to be evaluated in vivo.  
 
The second strategy we applied to generate HCV-specific polyfunctional T cells was 
DNA vaccination followed by electroporation. Previous studies by Ahlén et al (Ahlen, 
Soderholm et al. 2007) showed that a specific and effective CTL response against 
NS3/4A could be generated by using this method. The advantages of this vaccination 
procedure in contrast to a simple DNA injection are the higher DNA uptake and the 
increased immune stimulation caused by the electroporation itself (adjuvant effect) 
(Mathiesen 1999; Gronevik, Mathiesen et al. 2005). In paper III we focus our interest 
on NS5A because it is an essential protein in the HCV replication machinery (Blight, 
Kolykhalov et al. 2000; Tellinghuisen, Marcotrigiano et al. 2005) and it has also been 
proposed as a target for antiviral therapy (Coelmont, Hanoulle et al. 2010; Nettles, Gao 
et al. 2011; Lawitz, Gruener et al. 2012). Therefore we wanted to evaluate the 
immunological response to HCV NS5A after DNA vaccination in wild-type and NS5A 
transgenic mice and to do so we also identified novel murine CTL epitopes.  
 
The most interesting finding was that the NS5A-specific immune response could be 
raised in both wild-type and transgenic mice even if the second group showed 
evidences of tolerance (with lower levels of cytokine production after immunization). 
The two groups of mice were also challenged with tumor cells expressing NS5A after 
vaccination and an effective protection against tumor growth was found. In accordance 
with other vaccination studies were polyfunctional T cells are associated with an 
efficient immune response (Aagaard, Hoang et al. 2009; Burgers, Riou et al. 2009; 
Abel, Tameris et al. 2010; Derrick, Yabe et al. 2011; Lang Kuhs, Ginsberg et al. 2012; 
Tan, Eriksson et al. 2012) our findings highlight the validity of NS5A DNA vaccination 
since it was possible to generate a polyfunctional T cell response even in a tolerized 
mouse model. 
 
In conclusion we have successfully obtained polyfunctional T cells directed against 
NS3 and NS5A proteins by using two distinct approaches: TCR redirection and 
vaccination. This has implications for development of HCV treatments for patients who 
cannot be cured with the current antiviral therapy. The TCR-reagents may also serve as 
tools to gain better understanding of HCV immunology. 
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1 INTRODUCTION TO HEPATITIS C VIRUS 
INFECTION 
When people think about a worldwide viral infection starting in the early 80s, the first 
thought usually goes to the acquired immune deficiency syndrome (AIDS) and to the 
human immune deficiency virus (HIV). However, during the same period another 
blood-borne virus was also spreading silently and undetected and, like HIV this 
infectious agent was mostly targeting drug users and blood transfusion recipients. For 
several years, even for decades, most of the infected people did not notice any 
discomfort, not until the late disease stages when the real nature of the virus was 
already evident with a full attack to the liver often causing cirrhosis and cancer. This 
virus was identified and named hepatitis C virus in 1989 (Choo, Kuo et al. 1989). Since 
then several million people were diagnosed for hepatitis C virus infection and 
nowadays it is estimated that around 170 million people are infected and of these 130 
million are chronically infected and at risk for cirrhosis and liver cancer (Shepard, 
Finelli et al. 2005). In the Unites States, Europe and Japan the rate of transmission is 
currently decreasing thanks to disposable medical instruments and blood screening 
supply for the early diagnosis, but in developing countries the infection is spreading 
tremendously (John-Baptiste, Yeung et al. 2012). The traditional alpha-interferon based 
antiviral treatment has been long, expensive and cause of numerous side effects, 
besides, it was effective in only 50 to 80% of the cases depending on the viral genotype 
(John-Baptiste, Yeung et al. 2012). Recently two NS3/4A protease inhibitors, a first 
generation of direct acting antiviral (DAA) drugs, have been introduced in combination 
with pegylated interferon alpha and ribavirin for the treatment of patients infected with 
HCV genotype 1 with promising results (Sarrazin, Hezode et al. 2012). Despite this the 
increasing number of chronic hepatitis C cases is turning this disease into a very intense 
public health issue; therefore the need for a better treatment or therapeutic vaccine 
remains a major challenge for public health. 
 
 
1.1 THE HEPATITIS C VIRUS (HCV) 
The hepatitis C virus (HCV) is an enveloped single-stranded RNA virus belonging to 
the Flaviviridae family (Robertson, Myers et al. 1998). The genome is around 9.6 kb 
encoding for a long polyprotein which is then cleaved by both host and viral factors 
into different structural and non-structural proteins. The virion consists of an outer 
envelope composed of the structural E1 and E2 proteins covering the nucleocapsid 
(core) containing the RNA genome. In addition, several non-structural proteins are 
required for viral replication and packaging of the viral genome into the capsid (p7, 
NS2, NS3, NS4A, NS5A and NS5B) (Figure 1) (Kato, Yokosuka et al. 1990; Choo, 
Richman et al. 1991). 
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Figure 1. HCV genome and polyprotein. The HCV genome is a 9.6 kb RNA molecule 
of plus strand polarity. The genome is translated into a 3000 amino acid polyprotein 
that is then cleaved by cellular peptidases (black arrows) and viral peptidases (NS2 
green arrow and NS3 orange arrows) into three structural proteins (core, E1 and E2) 
and seven nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B). 
Modified from Georgel et al (Georgel, Schuster et al. 2010). 
 
 
The HCV genome is characterized by a high level of heterogeneity that allowed 
classification of 6 different viral genotypes (indicated with numbers from 1 to 6) 
differing of around 32% in their genome plus several subtypes (indicated with letters a, 
b, c etc.) differing of around 22% at the nucleotide level (Simmonds 1994).  
 
 
1.2 EPIDEMIOLOGY 
The HCV genotypes are differently distributed worldwide. Genotype 1 is for example 
the most prevalent genotype in Europe (Figure 2).  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 2. HCV genotype prevalence (World Health Organization 2009). 
C E1 E2 p7 NS2 NS3
NS
4A NS4B NS5A NS5B
9.6 kb RNA (+)
5’ UTR 3’ UTR
3000 aa polyprotein
Structural proteins Nonstructural proteins
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Being infected with different HCV genotypes implies different chances of virus 
clearance. Patients infected with genotype 2 and 3 are in fact curable with the standard 
care therapy (pegylated interferon-alpha in combination with ribavirin) in around 80-
90% of the cases, while patients infected with genotype 1 are cured only in around 40% 
of the cases (Fried, Shiffman et al. 2002; Patel and McHutchison 2004). Recently, the 
introduction of new antiviral drugs (two first generation NS3/4A protease inhibitors) 
for genotype 1 infected patients has improved substantially the cure rate for this group 
(Jacobson, McHutchison et al. 2011; Poordad and Khungar 2011). A second generation 
of DAAs is currently in preclinical or clinical development stage with drugs directed 
against several viral targets including NS3/4A, NS5B polymerase and NS5A (Sarrazin, 
Hezode et al. 2012). 
 
 
1.3 HCV LIFE CYCLE AND IMMUNE EVASION 
The route of infection, as previously mentioned, is basically blood-blood contact with 
the most affected individuals being, in the western developed world, intravenous drug 
users. However, a minor route of transmission is also represented by vertical 
transmission (mother-child), sexual exposure and other types of contacts with infected 
blood (tattoo etc) (World Health Organization Hepatitis C fact sheet n. 164, July 2012). 
After entering the blood stream the virus targets primarily the hepatocytes in the liver. 
To enter a cell, the envelope proteins E1 and E2 must bind to specific cellular receptors 
and so far it has been shown that the combination of at least four host molecules is 
needed: CD81 (Pileri, Uematsu et al. 1998), scavenger receptor type B class I 
(SCARB1) (Scarselli, Ansuini et al. 2002), claudin 1 (CLDN1) (Evans, von Hahn et al. 
2007) and occludin (OCLN) (Ploss, Evans et al. 2009). After the virion has attached to 
the cell surface, it is able to enter via clathrin-mediated endocytosis (Blanchard, 
Belouzard et al. 2006) while the release of the capsid into the cytosol is mediated by 
lowering the pH in the endocytes (Hsu, Zhang et al. 2003; Bressanelli, Stiasny et al. 
2004). Once inside the cell, the RNA+ HCV genome is translated into a long 
polyprotein via the IRES sequence located at the 5`UTR. As previously mentioned, this 
polyprotein is then cleaved by both host and viral proteases into ten proteins, of which 
one of the most important for immune evasion is the NS3/4A (Figure 3A-C). Another 
non-structural protein important for this purpose is NS5A, which is constituted by tree 
domains (I, II, and III) associated with different functions (Figure 3D).  
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Figure 3. (A) NS3/4A crystal structure (Chen, Njoroge et al. 2005) (PDB ID 2A4Q). 
(B) NS3 and NS4A schematic representation: NS3 is a 631 amino acid protein with two 
domains: serine protease domain (1-180), which cleaves the HCV polyprotein sites, and 
a RNA helicase domain (180-631): NS4A is a 54 amino acid protein that stabilizes NS3 
anchoring to the cytoplasmic side of the endoplasmic reticulum. The amino acids 22-34 
are the minimum domain for the serine protease co-factor activity (Bartenschlager, 
Ahlborn-Laake et al. 1993; Kwong, Kim et al. 2000). (C) NS5A crystal structure zinc 
finger in domain I (Tellinghuisen, Marcotrigiano et al. 2005) (PDB ID 1ZH1). (D) 
NS5A schematic presentation. Domain I (1-213) is a membrane anchoring domain 
responsible for the NS5A dimerization (Hwang, Huang et al. 2010) and essential for 
RNA replication; domain II (250-342) contains the elements responsible for the 
interference with IFN signaling; domain III (356-447) is involved in the assembly and 
production of HCV particles (Gale, Blakely et al. 1998; Appel, Zayas et al. 2008; 
Tellinghuisen, Foss et al. 2008). 
 
 
The NS3/4A complex has been shown to target at least three different host anti-viral 
elements: the mitochondrial antiviral signaling protein (MAVS), the TIR domain-
containing adaptor inducing IFN-β (TRIF) and the T cell protein tyrosine phosphatase 
(TCPTP) (Brenndorfer, Karthe et al. 2009; Morikawa, Lange et al. 2011) (Figure 4). 
NS5A domain I is a membrane-anchoring domain that seems to be essential for RNA 
replication (Tellinghuisen, Foss et al. 2008); domain II was suggested to interfere with 
the interferon signaling pathways through interferon-dependent induced protein kinase 
R (PKR) (Gale, Blakely et al. 1998; Appel, Schaller et al. 2006) and also to impair 
HCV-specific T cell response in the liver (Kriegs, Burckstummer et al. 2009) while 
domain III seems to be connected to the assembly and production of novel viral 
particles (Appel, Zayas et al. 2008).  
The mechanism of virion assembly can be divided in two steps: early assembly located 
in the cytosolic side of the ER where core, NS5A and NS3 form immature non-
infectious virions; late assembly that consists in the acquisition of the lipid envelope 
1 631180
1 22 34 54
Serine
protease 
minimum protease co-factor 
Helicase
NS4A
NS3
1 213 250 342 356 447
Domain
I
Domain
II
Domain
III NS5A
A
B D
C
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together with E1 and E2; NS2 seems to mediate the interaction between E1, E2 and the 
immature virions conferring infectivity (Jones and McLauchlan 2010). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Interaction of HCV and the host cell. During the HCV replication cycle many 
host cell factors are involved (red). Heparan sulfate, low-density lipoprotein receptor 
(LDLr), scavenger receptor B1 (SR-B1), CD81, claudin 1 (CLDN1) and occludin 
(OCLD) are involved for the attaching and entry steps; autophagy proteins, miRNA-
122 and polypyrimidine tract binding protein 1 (PTB-1) are involved in the translation, 
maturation and replication steps; ApoE, ApoB, heat shock protein 70 (Hsp70) e 
microsomal transfer protein (MTP) are involved in the assembly and egression steps. 
Core, NS3 and NS5A HCV proteins also interact with the IFN signaling pathways. 
Modified from Georgel et al (Georgel, Schuster et al. 2010). 
 
 
1.4 CLINICAL FEATURES 
The infection with HCV can results in two different outcomes: an acute infection which 
is mostly followed by spontaneous viral clearance (about 25% of cases) or, if viremia 
persists for more than six months, a chronic infection (about 75% of the cases). Several 
factors have been associated with viral clearance including age (less than 40 years old) 
(Micallef, Kaldor et al. 2006), female gender (Bakr, Rekacewicz et al. 2006), disease 
presented with lower viral load (Villano, Vlahov et al. 1999) and sustained T cell 
responses against nonstructural proteins (Ward, Lauer et al. 2002; Rehermann 2009).  
In the majority of cases however, the disease becomes chronic with persistently 
detectable viral load and anti-HCV antibodies. The liver is affected by a gradual 
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inflammatory damage followed by progressive fibrosis that can lead to cirrhosis and 
hepatocarcinoma. 
 
 
1.5 LIVER TOLERANCE AND T CELL IMMUNITY 
In the case of HCV infection, the first site of antigen presentation to the lymphocytes is 
particularly important as it is believed that the unique features of the liver would induce 
immune response into tolerance (and then chronic infection) rather than immunity 
against the invading pathogen (Crispe 2009) as that several cell types in liver have 
tolerogenic potentials (see below). 
 
 
1.5.1 Liver tolerance 
It has been calculated that approximately 75% of the blood present in the liver comes 
directly from the gut through the portal vein; therefore being loaded with food and 
bacterial antigens (Bowen, McCaughan et al. 2005). This would be the main reason for 
making the liver milieu more prone to drive immune cells towards tolerance instead of 
immune response (Crispe 2009). In line with this, the local and systemic tolerance 
effect has also been attributed to specialized liver resident cells expressing anti-
inflammatory mediators and inhibitory cell surface ligands for T cell activation (Figure 
5). In the subsequent paragraph these different antigen presenting cell types will be 
discussed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Possible mechanisms of T cell tolerance in the liver. Liver sinusoidal 
endothelial cells (LSEC) express adhesion molecules that facilitate the trapping of 
activated T cells, Kupffer cells (KC) express also TRAIL and Fas ligand (FasL) which 
make T cells undergo apoptosis or be phagocytosed. In addition, T cells are also 
exposed to immunosuppressive cytokines, like IL-10 and TGF-β1 and to inhibitory 
ligands like PD-L1 coming also from hepatic stellate cells (HSC). Modified from 
Crispe et al (Crispe 2009). 
Hepatocytes
HSC
LSEC
KC
KC
LSEC
T cell
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Conventional antigen presenting cells (APCs). These are dendritic cells (DCs), which 
take up the antigens at the site of the infection, the liver in this case, and then migrate to 
the lymph nodes in order to present the antigen to specific T cells. DCs isolated from 
liver tissue express very low levels of class II major histocompatibility complex (MHC) 
molecules and co-stimulatory molecules (CD40, CD80, CD86) exhibiting an immature 
phenotype (Racanelli and Rehermann 2006; Selmi, Mackay et al. 2007; Crispe 2009). 
Accordingly, liver DCs produce preferentially IL-10 instead of Th1 activating 
cytokines thereby promoting a Th2 cytokine response. This feature also seems to favor 
CD4+CD25+Foxp3+ regulatory T cells (Goddard, Youster et al. 2004; Bamboat, 
Stableford et al. 2009). 
 
Liver sinusoidal endothelial cells (LSECs). These cells constitutively express MHC 
class I and II as well as co-stimulatory molecules like CD40, CD80 and CD86. They 
are able to take up antigens and present them to CD4+ and CD8+ T cells. The induction 
of tolerance correlated also with the induction of negative co-stimulatory molecule PD-
L1 by LSECs (Knolle, Uhrig et al. 1998; Limmer, Ohl et al. 2000; Knolle and Limmer 
2001; Limmer, Ohl et al. 2005). 
 
Kupffer cells (KCs). These are tissue resident macrophages able to release pro-
inflammatory cytokines such as IL-1, IL-6 and TNF-α thus promoting infiltration of 
neutrophilic granulocytes involved in elimination of bacteria (Knolle, Lohr et al. 1995). 
TNF-α is a cytotoxic factor in the liver because it leads hepatocytes to apoptosis under 
pathological conditions (Schumann and Tiegs 1999; Wullaert, van Loo et al. 2007). On 
the contrary, a low concentration of TNF-α makes hepatocytes resistant to apoptosis 
(Sass, Shembade et al. 2007; Haimerl, Erhardt et al. 2009). KCs also produce IL-2 and 
IL-18. These cytokines, among others, activate NK cells to produce antiviral IFN-γ. 
However after this initial production of pro-inflammatory cytokines KCs release IL-10 
which downregulates the production of TNF-α, IL-6 and other cytokines (Knolle, Lohr 
et al. 1995) and probably contribute to induce tolerance. 
 
Hepatic stellate cells (HSCs). HSCs have mainly been described for their participation 
in hepatic fibrosis and storage of vitamin A. However, they have also been shown to 
function as APCs and to be able to present proteins or lipid antigens to CD8+, CD4+ 
and NKT cells (Winau, Quack et al. 2008). Because of their ability to store vitamin A 
and to produce TGF-β in response to inflammation and injury they may also exhibit 
tolerogenic functions. CD4+ T cells can in fact be converted into induced regulatory T 
cells by vitamin A derived retinoic acid and/or TGF-β (Strober 2008). Moreover 
activated HSCs express PD-L1 (Yu, Chen et al. 2004). 
 
Hepatocytes. Hepatocytes mainly perform metabolic functions. However, they also 
seem to participate to the immunoregulation in the liver by their ability as APCs. It has 
been shown that PD-L1 is induced in hepatocytes by viral infection as well as by type I 
and type II interferons (Muhlbauer, Fleck et al. 2006) together with IL-10 that, as also 
mentioned previously, is the dominant cytokine produced by resident DCs, KCs and 
LSEC. 
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1.5.2 T cells in HCV infection 
In general the CD8+ cytotoxic T lymphocytes (CTL) are essential for an effective 
immune response to all viral infections (McMichael and Hanke 2003). Viral replication 
is mainly suppressed by CTLs in three different ways: 1) production of IFN-γ; 2) lysis 
of infected cells via Fas-FasL interaction and 3) lysis of target cells by delivery of 
granzyme and perforin (this third mechanism is the most rapid and usually the most 
important in anti-viral defense). An effective antiviral CTL response is defined as a 
response that reduces either the viral load or the incidence or prevalence of virus-
associated disease (Bangham 2009). In the following paragraph the role of T cells 
during HCV infection will be discussed. 
 
Both virus specific CD4+ and CD8+ T cell populations are determinant for the 
outcome of HCV infection. CD4+ T cell help is in fact required for a successful CD8+ 
CTL cell mediated viral clearance (Neumann-Haefelin, Spangenberg et al. 2007). As 
previously mentioned, viral replication can be suppressed by lysis of target cells by 
specific CTLs, but in the case of HCV, a non-cytolytic mechanism of viral clearance 
would be preferable as infected cells being cured instead of killed would result in less 
hepatotoxic effects (Guidotti and Chisari 2006). In the early phase of acute HCV 
infection (4-8 weeks after infection) it is possible to detect a vigorous and specific 
CD8+ T cell response against several viral epitopes (Gruner, Gerlach et al. 2000; 
Thimme, Oldach et al. 2001). These virus specific CD8+ T cells present a so-called 
“stunned phenotype” because they are not able to secrete antiviral cytokines like IFN-γ 
(Lechner, Wong et al. 2000; Thimme, Oldach et al. 2001).  In a subsequent phase of 
infection these stunned cells gain back their capacity to secrete antiviral cytokine and 
this is associated with decline of viremia and, in the resolving infection, with viral 
clearance (Neumann-Haefelin, Spangenberg et al. 2007). However in the chronic phase 
of HCV infection, the HCV-specific T cells appear impaired in mainly two ways:  by T 
cell exhaustion and viral escape. T cell exhaustion is defined by impaired CD8+ T cell 
effector functions and characterized by co-expression of several inhibitory receptors 
such as PD-1, 2B4 and CD160 while viral escape is not a universal mechanism. It is in 
fact limited by fitness cost, for example by the inability to tolerate mutations within 
highly constrained epitopes (Klenerman and Thimme 2012). 
 
 
1.5.3 Intrahepatic lymphocytes 
T cells. Several studies on experimentally infected chimpanzees have shown that a 
strong HCV-specific T cell response inside the liver is important for reduction of viral 
load and clearance of acute infection (Weiner, Erickson et al. 1995; Cooper, Erickson et 
al. 1999; Thimme, Bukh et al. 2002; Shoukry, Grakoui et al. 2003). However, in spite 
that intrahepatic HCV-specific CD8+ T cells are present in the majority of patients with 
chronic HCV infection, it is clear that a large fraction of these CD8+ T cells are 
impaired especially in their ability to secrete IFN-γ (Spangenberg, Viazov et al. 2005; 
Neumann-Haefelin, Timm et al. 2008). A subset of HCV-specific intrahepatic CD8+ T 
cells can also secrete IL-17, and was found to have a possible association with low 
grade of liver inflammation (Grafmueller, Billerbeck et al. 2012). Interestingly this 
subset shows a different antigen-specificity compared with IFN-γ  producing CD8+ T 
cells, and whether they exhibit antiviral mechanisms remain to be determined. The 
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localization of CD8+ T cells within the liver is required for termination of HCV 
replication while the control of viremia is dependent on a rapid and massive expansion 
of CTLs (Shoukry, Grakoui et al. 2003).  A strong intrahepatic T cell response is 
critical to clear the infection but it was estimated that around 70% of the infected 
individuals fail to mount this response and become chronic (Bowen, McCaughan et al. 
2005). Major factors contributing to the intrahepatic T cell failure are likely to be the 
liver tolerance effect as we previously discussed and the continue rise of viral escape 
mutations. 
 
NK and NKT cells. The liver also has an unusually high frequency of natural killer 
(NK) cells and NK T (NKT) cells. In patients with chronic HCV infection, NK cells are 
reduced in their frequency and functionality. The intrahepatic NK cells in particular 
show dysfunctional features with a reduced TRAIL and CD107a expression, indicating 
the existence of a lytic defect in the NK-cells (Varchetta, Mele et al. 2012). Instead, IL-
10 and TGF-β are produced resulting in production of Th2 cells and Tregs. The NKT 
cells are also highly abundant in the liver constituting up to 50% of intrahepatic 
lymphocytes. They represent a unique subset of T lymphocytes that have TCR and NK 
markers. A decrease in intrahepatic NKT cells has also been reported in chronic HCV 
patients. NKT cells have a role in the deleterious effects mediated by immune cells 
during chronic liver inflammation, as the numbers of activated NKT cells have been 
found to correlate with the degree of hepatocellular damage and onset of fibrosis (Nuti, 
Rosa et al. 1998; de Lalla, Galli et al. 2004). 
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2 ANTIVIRAL THERAPY 
Pegylated interferon-alpha and ribavirin have constituted as the standard of care (SOC) 
of chronic HCV infection during the past decade. SOC therapy is often long and causes 
considerable side effects including fewer, fatigue, myalgia anemia, depression, skin 
rash and gastrointestinal symptoms. This combination had a synergistic antiviral effect 
but, depending on the HCV genotype, it was efﬁcient in only 33%-42% of patients with 
genotype 1 and in 90% of those with genotypes 2 and 3 (Fried, Shiffman et al. 2002). In 
2011, two protease inhibitors (telaprevir and boceprevir) were approved for use in 
combination with SOC therapy for genotype 1 patients and further improved the 
treatment efficiency to around 70% (Jacobson, McHutchison et al. 2011; Poordad and 
Khungar 2011). As for HIV, it is likely that, due to the pre-existing viral mutants and 
the high mutation rate of the HCV genome, drug resistance will eventually emerge 
during treatment with specific viral inhibitors; therefore it has been anticipated that a 
combination of drugs acting in different stages of the viral life cycle needed to be 
developed (Figure 6). In addition to these two first-generation NS3/4A inhibitors, there 
is now a large number of new HCV inhibitors in clinical development, which are 
discussed below. 
 
Other NS3/4A inhibitors with better pharmacokinetic and tolerability than telaprevir 
and boceprevir have been developed. TMC435 (Tibotec/Janssen-Cilag) and BI201335 
(Boehringer-Ingelheim) for example, showed high rates of rapid virological response, 
together with sustained virological response rates of the same order or higher than those 
reported with telaprevir and boceprevir (Fried, Hadziyannis et al. 2011; Gane, Rouzier 
et al. 2011). These drugs are now evaluated in phase III clinical trials in combination 
with pegylated IFN-α and ribavirin (Sarrazin, Hezode et al. 2012). 
 
Nucleoside/nucleotide analogue inhibitors of the HCV RNA-dependent RNA 
polymerase. These molecules function as false substrate for the polymerase so their 
incorporation in the newly synthetized RNA actually results in the termination of the 
replication process (Sarrazin, Hezode et al. 2012). Though they have a low “genetic 
barrier” to resistance, i.e. single amino acid substitutions are able to confer drug 
resistance in vitro, the resistant virus variants are poorly fit, thus may be considered as 
high ”barrier” resistance DAAs. 
 
Non-nucleoside inhibitors of the  HCV RNA-dependent RNA polymerase. The structure 
of the RNA-dependent RNA polymerase can be compared to the shape of a right hand. 
The non-nucleoside inhibitors create a steric bulk for the polymerase binding to one of 
the four allosteric sites at the surface of the protein. Inhibitors binding the “thumb 
domain I” or the “palm domain I” are designated BI207127 (Beaulieu, Jolicoeur et al. 
2010), VCH-759 (Cooper, Lawitz et al. 2009), and ABT-333, ABT-072 (Abbott) 
(Sarrazin, Hezode et al. 2012) and Tegobuvir (GS-9190) Gilead (Shih, Vliegen et al. 
2011) respectively. All these drugs are active against HCV genotype 1. For all the 
molecules resistant viral mutants have been found (Sarrazin, Hezode et al. 2012). 
 
NS5A inhibitors. The first inhibitor tested in clinical trials was Daclatasvir (BMS-
790052), which binds the protein domain I and is specific for HCV genotype 1 (Gao, 
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Nettles et al. 2010). This drug is currently in phase II clinical trials in combination with 
pegylated interferon-alpha and ribavirin, or in interferon-free trials with NS3/4A 
protease inhibitors or with nucleotide analogues (Sarrazin, Hezode et al. 2012). Other 
NS5A inhibitors in developing phase are BMS-824393 (Bristol-Myers Squibb), 
AZD7295 (Arrow Therapeutics/AstraZeneca), PPI-461 (Presidio) and GS-5885 
(Gilead) (Gane, Roberts et al. 2010; Gao, Nettles et al. 2010; Nettles, Gao et al. 2011). 
 
Host-targeting agents (HTA). HTAs are novel antiviral agents that target various host 
cell factors required during the HCV life cycle. The strengths with HTA are high 
genetic barrier to resistance, the pan-genotypic antiviral activity, and possible 
complementary mechanisms of action with DAAs. Currently tested in clinical trials are 
inhibitors against host cellular target such as SR-BI (ITX5061), miR122 (Miravirsen), 
HMGCoA reudctase (Statins), Cyclophilin A (SC-635 and Alisporivir) and 
Glucosidase (MX-3253) (Zeisel, Lupberger et al. 2012).  So far with cyclophlin 
inhibitors no resistant viral mutants have been identified (Flisiak, Feinman et al. 2009).  
 
Although DAAs increase the response to IFN-based anti-HCV therapy, they also lead 
to selection of drug-resistant variants. Given the reported side effects and potential 
drug-drug interactions, anti-HCV DAAs are not approved for several groups of patients 
including those undergoing liver transplantation, immunosuppressed or HCV/HIV co-
infected (Sarrazin, Hezode et al. 2012). Thus, in spite that early clinical trials have 
shown excellent outcomes for DAA combinations for treating HCV patients, novel 
antivirals for the difficult-to-treat patients need to be developed. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The red boxes indicate possible antiviral strategies targeting viral and host 
factors mediating HCV infection. Immune modulators and ribavirin analogs are shown 
outside the cell because they target multiple pathways. Modified from Georgel et al 
(Georgel, Schuster et al. 2010). 
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3 VACCINE 
The purpose of vaccination is to elicit a strong, specific and effective immune response 
that can be acquired by the host as immunological memory and be recalled rapidly 
when the pathogen is re-encountered. Generating a strong CTL response is important 
for the resolution of viral infections. In the case of chronic diseases such as HCV, the 
vaccine can be intended also as therapeutic to boost or redirect the already existing but 
not optimal antiviral immunity of the host. Developing an HCV vaccine with an 
existing therapy and in parallel to the introduction of new antiviral drugs like Telaprevir 
and Boceprevir, can appear dispensable. However in this respect, one must keep in 
mind the current treatments are not efficient in all patients and are accompanied with 
very high cost and adverse effects (Tungol, Rademacher et al. 2011). The current state 
of HCV vaccines in clinical trials, both prophylactic and therapeutic, is discussed here. 
 
Prophylactic vaccine. The aim here is to prevent the infection thus avoiding completely 
the need of a costly and unpleasant therapy. The ideal mechanism of action would 
basically be to induce a B cell response with effective neutralizing antibodies in parallel 
to the stimulation of both T helper cells and CTLs. Clinical studies on prophylactic 
vaccines are thus often designed to induce T-cell responses that target the non-
structural proteins of HCV, or antibody responses that target the E1E2 envelope 
proteins (Feinstone, Hu et al. 2012). The idea is that elimination of persistent infection 
will prevent chronic liver disease, which is the major problem with HCV infection 
(Seeff 2002). Ongoing and completed clinical studies are the vaccines developed by 
Chiron/Novartis and Okairos. Purified recombinant viral envelope protein vaccine with 
Chiron´s MF59 adjuvant showed promising results in the preclinical and phase I 
clinical trials, with high levels of neutralizing antibodies and a strong T helper response 
(Frey, Houghton et al. 2010; Houghton 2011). Adenovirus- or MVA vector-delivered 
NS3 or NS3-NS5B vaccines conducted by Okairos or NIAID also represent interesting 
prophylactic vaccine candidates. Using new adenoviral vectors based on rare serotypes 
[human adenovirus 6 (Ad6) and chimpanzee adenovirus 3 (ChAd3)] expressing NS 
proteins from HCV genotype 1b, Okairos Ad6NSmut/AdCh3NS3mut vaccine 
succeeded to generated a broad T cell response and the vaccine is going to be tested in 
a phase II clinical trial (Barnes, Folgori et al. 2012). An important issue is to define 
functional markers of protection for a vaccine candidate and these markers need to be 
evaluated during the developing phase, such markers can be antibody epitopes, T-cell 
phenotypes, homing profiles, central and effector memory T-cell phenotypes, T-helper 
function and proliferation (Feinstone, Hu et al. 2012). As exemplified by the HIV 
vaccine research, the experience is that if a T cell vaccine candidate fails to clear the 
virus the major reason is that the virus specific CD8+ T cells are secreting just one 
cytokines, mostly IFN-γ, therefore it is desirable to generate a polyfunctional T cell 
response instead (Harari, Bart et al. 2008).  
 
Therapeutic vaccine.  They aim here is to rescue a potent T cell immune response in 
chronic patients. These vaccines are to be considered as an addition to the standard 
therapy, and not a substitutive. A number of vaccine candidates are currently in clinical 
trials. Candidates that are entering phase II trials are those developed by Transgene 
(TG4040), Okairos (AdCh3NS3mut) and ChronTech Pharma (CHRONVAC-C). 
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TG4040 is based on the non-pathogenic MVA vector expressing the HCV NS3-NS5B 
proteins (Habersetzer, Honnet et al. 2011) and it is now in clinical phase II trial. The 
CHRONVAC-C DNA vaccine encoding synthetic codon-optimized HCV NS3/4A 
genes delivered intramuscularly with electroporation to enhance the immune response 
is also an interesting candidate, as it has been shown in combination with SOC to be 
able to reduce viral load in chronically infected HCV patients. A special safety issue 
has been pointed out for therapeutic vaccines against HCV since these vaccines are 
supposed to induce a strong HCV-specific CTL response the major concern consists in 
the risk of liver damage. So far none of the vaccine candidates previously described has 
shown any adverse side effect, but clearly none of them have yet succeeded to clear the 
virus completely (Feinstone, Hu et al. 2012). 
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4 IN VIVO AND IN VITRO MODELS FOR STUDIES OF 
HCV INFECTION 
In this section, current available in vitro (cell culture) and in vivo (animals) models for 
the study of HCV infection will be discussed. 
 
 
4.1 IN VITRO MODELS 
In the early stage of HCV research field all the viral clones that were trying to 
propagate in vitro resulted to be non-functional due to the high mutation rate of the 
HCV RNA dependent RNA polymerase. This problem was solved by the construction 
of consensus genomes based on a master sequence representing the majority of viral 
genomes in a given sample (Boonstra, van der Laan et al. 2009). The first 
complementary DNA full-length functional clone of HCV was derived from a genotype 
1a strain and its RNA transcripts were able to infect chimpanzees after intrahepatic 
inoculation (Kolykhalov, Agapov et al. 1997; Yanagi, Purcell et al. 1997). After this 
first consensus genome several others were made for genotypes 1 and 2 but they were 
all unable to replicate in vitro (Bartenschlager and Sparacio 2007). The first system that 
allowed HCV replication in vitro was created modifying the consensus genome Con1 
by replacing the structural proteins with the neomycin resistance gene and adding a 
second internal ribosome entry site to promote translation of the nonstructural proteins 
(Lohmann, Korner et al. 1999). This so-called subgenomic replicon (or bicistronic 
replicon) was transfected in specific cell lines and, after selection, the cell colony in 
which the replicon had the highest levels of replication was isolated (Lohmann, Korner 
et al. 1999; Pietschmann, Lohmann et al. 2001). Highly permissive cells are the Huh7.5 
and Huh7-Lunet cells (Blight, McKeating et al. 2002; Friebe, Boudet et al. 2005). 
These replicon systems have been used to study the HCV replication process as well as 
to test antiviral compounds targeting NS3 and NS5B (Bartenschlager 2005). An 
improvement of this system was done creating subgenomic replicons containing 
reporter genes like the firefly luciferase or fluorescent proteins (Lohmann, Hoffmann et 
al. 2003; Jones, Murray et al. 2007; Schaller, Appel et al. 2007). This system was 
subsequently modified with the introduction of the HLA-A2 molecules by lentiviral 
transduction in the Huh7-Lunet cells and the introduction of the luciferase gene in the 
HCV replicon directly under the control of the HCV replication machinery (Jo, Aichele 
et al. 2009). Monocistronic replicons have also been generated by inserting green 
fluorescent protein in the NS5A coding region with the purpose of discriminate 
between viral genomes in studies about HCV superinfection exclusion (Schaller, Appel 
et al. 2007). All these replication models however do not allow the secretion of viral 
particles and this is probably caused by adaptive mutations that are needed to enhance 
replication rates but on the other hand impair viral assembly (Pietschmann, Zayas et al. 
2009). The situation changed when a subgenomic replicon from the JFH-1 HCV strain 
(genotype 2a) was constructed (Date, Miyamoto et al. 2007). Transfection of Huh7 and 
Huh7.5 cells with the fulllength JFH-1 genome or with a recombinant chimeric genome 
(combination of JFH-1 and the J6 genotype 2a isolate) resulted in the secretion of viral 
particles that were infectious in cultured cells and animal models (Lindenbach, Evans et 
al. 2005; Wakita, Pietschmann et al. 2005; Zhong, Gastaminza et al. 2005; Lindenbach, 
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Meuleman et al. 2006). Another important in vitro model for the study of early steps of 
virus binding and cell entry is the pseudoparticle system. This system consists in the 
incorporation of HCV glycoproteins E1 and E2 into retroviral or lentiviral cores that 
are highly infectious and that can mimic the viral entry of HCV (Bartosch, Dubuisson 
et al. 2003). Thanks to this model it was possible to identify several viral entry factors 
like glycosaminoglycan, low density lipoprotein receptor and claudin-1 (von Hahn and 
Rice 2008). 
 
 
4.2 IN VIVO MODELS 
Chimpanzee. Chimpanzees have so far been the best model for studies on HCV 
infection and related innate and adaptive host immune response. However, the HCV 
disease progression is somewhat different since chimpanzees more commonly clear the 
HCV infection spontaneously compared to humans, and the clinical manifestations are 
milder. Although, most of the knowledge that was acquired with chimpanzee studies 
would in fact not have been possible to conduct in human studies especially since the 
chimpanzee model allows frequent sampling of the liver for the analysis of HCV-
specific T cell responses or gene expression profiles (Bukh 2004). Key aspects of HCV 
cellular immunity were also discovered thanks to this model as e.g. that acute resolving 
infection is associated with strong, intrahepatic HCV-specific CD4+ and CD8 + T cell 
responses (Thimme, Bukh et al. 2002; Major, Dahari et al. 2004) and that HCV 
persistence is associated with weaker responses and/or development of viral escape 
mechanisms including mutations in viral epitopes recognized by CD8+ T cells (Fuller, 
Shoukry et al. 2010; Callendret, Bukh et al. 2011). Furthermore, the role of the CD4+ 
and CD8+ T cell response was investigated in chimpanzee studies in which these cell 
populations have been depleted by using specific antibodies. Depletion of CD8+ T cells 
caused a prolonged viremia after challenge and the clearance of the virus coincided 
with the reappearance of these T cells in the liver (Shoukry, Grakoui et al. 2003). 
Depletion of CD4+ T cells instead resulted in HCV persistence after challenge 
indicating that an inadequate CD4+ response affects the outcome of HCV infection 
(Grakoui, Shoukry et al. 2003). Chimpanzees are also the only animals that can be used 
to evaluate the immunogenicity and efficacy of HCV vaccine candidates. 
 
Mouse models. There are two models based on the SCID background mice; these mice 
lack both the T and B cells compartments. The first one is the uPA-SCID model 
(Mercer, Schiller et al. 2001) with mice carrying a genetic mutation that causes 
degeneration of hepatocytes. In this model, mice can subsequently be engrafted with 
primary human hepatocytes and subsequently infected with HCV. The second one is 
the Fah-/-Rag2-/-IL2rg-/-[FRG] model (Bissig, Wieland et al. 2010) where mice also 
have a genetic defect that causes liver destruction. However in this model, this is 
prevented by oral administration of a drug keeping the mice healthy until the 
engraftment with human hepatocytes. This results in a human liver repopulation of up 
to 95%.  
Since these models are immunodeficient, they cannot be used to evaluate the adaptive 
immune response towards HCV. However, they have been very useful to study innate 
responses, virus neutralization, virus-receptor interactions and also to evaluate novel 
antiviral drugs. To overcome the lack of adaptive immunity in the SCID based models 
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two additional models have been generated. The first one is the AFC8-huHSC/hep 
mouse model that permits engraftment of human hepatocyte progenitor stem cells and 
hematopoietic stem cells so that mice will have a repopulation of the liver with human 
hepatocytes and an immune reconstitution with human leukocytes (Washburn, Bility et 
al. 2011). The other model is the Rosa26-Fluc model, which is based on an immune-
competent mouse expressing human cell-surface receptors required for HCV entry 
(Dorner, Horwitz et al. 2011). However, the use of these models is limited to the study 
of only specific aspects of the HCV life cycle as HCV infection often results in 
undetectable viremia. 
 
HCV transgenic mouse models Several HCV transgenic mouse model systems have 
been established. Currently, transgenic mice expressing HCV structural proteins or 
non-structural proteins e.g. the NS2, NS3, NS4A, NS4B, NS5A and NS5B either 
individually or in various combinations have been made. These HCV proteins are often 
designed to be constitutively expressed under the control of liver-specific promoters 
(Lerat et al 2011). Such models are useful for immunological studies of HCV. Because, 
if a potent HCV-specific immune response can be primed by vaccination, the 
transgenic mouse model would enable studies whether it has effect on the transgene in 
the liver. Moreover, the priming event may be further complicated by the fact that the 
preexisting T cells have been modulated by the persistence of HCV antigen. Since such 
issues are difficult to assess in the absence of an infectious small-animal model, the 
HCV transgenic models thus represent an important alternative. 
 
Other small animal models. These models have generally a limited use for several 
reasons. In the tree shrews model (Tupaia belangeri), these small non rodents can be 
infected with HCV but with a low and variable rate (Amako, Tsukiyama-Kohara et al. 
2010). Tolerized immunocompetent rats with transplanted human hepatoma cells have 
also been generated (Wu, Konishi et al. 2005) but they could not be used to study the 
cellular immune response against HCV infected cells. 
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5 ADOPTIVE TRANSFER OF ANTIGEN-SPECIFIC T 
CELLS 
The adoptive transfer of antigen-specific effector cells, in particular CTL, is emerging 
as a promising therapeutic approach for the treatment of tumors and viral infections 
(Rosenberg 1999; Blattman and Greenberg 2004). One of the most promising 
applications is the ex-vivo manipulation of peripheral blood lymphocytes (PBL) from 
either the same patient or from a suitable donor, their clonal selection (Rosenberg, 
Spiess et al. 1986; Dudley, Wunderlich et al. 2002; Dudley, Wunderlich et al. 2005), or 
genetic manipulation (Morgan, Dudley et al. 2006) to expand the wanted antigen-
specific population and the reinfusion of these cells into the recipient. 
 
 
5.1 T CELL THERAPY AND HCV 
The antigen-specific T cell therapy has been successfully used to treat melanoma 
(Rosenberg, Yannelli et al. 1994; Dudley, Wunderlich et al. 2001; Yee, Thompson et 
al. 2002) and viral infections such as CMV (Walter, Greenberg et al. 1995; Einsele, 
Roosnek et al. 2002) and EBV (Heslop, Ng et al. 1996; Bollard, Aguilar et al. 2004). In 
the field of HCV, so far no attempts to use antigen-specific T cells have been made 
even though this approach has been proposed. In particular the proposed approach is 
focused on the TCR gene transfer of TCRs specific for the HCV NS3 antigen (Zhang, 
Liu et al. 2010). Another interesting study has investigated the adoptive 
immunotherapy of liver allograft-derived lymphocytes treated with IL-2 and the CD3-
specific mAb OKT3 in HCV-positive liver transplanted patients (Ohira, Ishiyama et al. 
2009). The result of this study showed that HCV RNA titers in the sera of recipients 
who received the HCV -specific lymphocytes were significantly lower than the patients 
who did not receive these cells. 
 
 
5.2 TCR GENE TRANSFER 
Like for any other kind of gene transfer, the TCR gene transfer has the purpose of 
adding a new external gene into the recipient cell. In the case of T cells, transferring a 
new TCR would mean that the recipient cell would gain a new antigen specificity thus 
being re-directed to a new target (Dembic, Haas et al. 1986). The results of completed 
clinical trials (Morgan, Dudley et al. 2006; Johnson, Morgan et al. 2009) have shown 
that despite TCR gene therapy is possible, several important questions, especially 
regarding the efficacy towards the risks, still remain to be addressed. However, some 
important points that emerged from these studies are that for successful TCR gene 
therapy, the generation of high-avidity T cells is a prerequisite and that coreceptor-
independent TCRs would allow the generation of both cytotoxic and helper cells to 
combine the antigen-specific effect (Kieback and Uckert 2010). In the following 
sections the main problems of TCR gene transfer are discussed and a solution is 
proposed. 
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5.2.1 Expression and correct function of exogenous TCRs  
To activate a T cell and obtain an effector function, the number of TCR molecules 
engaged with the peptide-MHC is crucial (Viola and Lanzavecchia 1996; Hudrisier, 
Kessler et al. 1998). It is known that mature T cells express on their surface between 
10000 to 40000 TCR molecules and this expression level directly correlates with the 
antigen responsiveness (Blichfeldt, Munthe et al. 1996; Schodin, Tsomides et al. 1996; 
Labrecque, Whitfield et al. 2001). Therefore, whether a cell presents a lower number of 
TCRs, this would require a higher peptide concentration to become activated. This is of 
particular importance when an exogenous TCR is transferred into a new T cell and will 
have to compete with the endogenous TCR for surface expression. Other major limiting 
factors to consider are the correct assembly of the exogenous TCR with the CD3z 
complex (as the number of CD3z is limited) (Minami, Weissman et al. 1987) and the 
mispairing with the endogenous TCR alpha and beta chains that can lead not only to a 
reduced exogenous TCR surface expression but also to a potentially dangerous new 
antigen specificity. 
In this section a number of possible solutions to this problem are described. 
 
Codon optimization. Allowing an optimal expression of the exogenous TCR is possible 
by improving the translation relevant sequences at the mRNA level. This is easily 
obtainable by modifying the codon usage of the mRNA structural elements 
(Gustafsson, Govindarajan et al. 2004). Several studies demonstrated that codon 
optimization improves the surface expression of exogenous TCRs in transduced cells 
and the tetramer binding for both human and murine TCRs (Scholten, Kramer et al. 
2006; Hart, Xue et al. 2008). 
 
RNA interference (RNAi). The aim of using RNAi would in this case be to completely 
shut off the expression of the endogenous TCR so that the transduced T cell will only 
express the exogenous TCR. In this respect, it has been shown that targeting the 
constant region of the endogenous TCR with a specific microRNA decreased the 
expression of this TCR while the exogenous one was not affected thanks to the codon 
optimization (Okamoto, Mineno et al. 2009). 
 
Removal of glycosylation sites. It has been shown that removing N-glycosylation sites 
improves the functional avidity of transduced T cells (Kuball, Hauptrock et al. 2009). 
 
Expression vector. The ideal vector should give the possibility to carry big inserts (i. e. 
alpha and beta TCR chains plus co-stimulatory molecules and selection markers) and 
have a high transduction rate targeting only the wanted population without the need of 
bulk activating the T cells. It has in fact been shown that activation induces cell 
division that can influence negatively the in vivo efficacy (Gattinoni, Finkelstein et al. 
2005). Moreover, an ideal vector should express the transgene for a reasonably long 
time without being immunogenic for the host and, possibly, its manufacture should be 
cheap and easy. Unfortunately such an ideal vector is not yet available but one very 
interesting approach was proposed by Perro et al (Perro, Tsang et al. 2010). In this 
study it was found that a combination of IL-15 and IL-21 facilitated lentiviral TCR 
gene transfer into non-proliferating T cells and the obtained redirected T cells showed a 
multifunctional phenotype producing IL-2, IFN-γ and TNF-α in an antigen-specific 
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manner. The most common vectors used for gene therapy with their advantages and 
disadvantages are summarized in Table 1.  
 
Table 1. Advantages and disadvantages of the most common vectors used for gene 
transfer. Modified from Mountain et al  (Mountain 2000). 
 
Vector Advantages Disadvantages 
Adenovirus High transfection efficiency ex 
vivo and in vivo 
Proliferating and non- 
proliferating targets 
Clinical experience acquired 
Insert limit 7.5 kb 
Immunogenicity for the host 
Short duration of expression 
Manufacture quite difficult 
Safety concerns for self-replicating 
particles 
Retrovirus High transfection efficiency ex 
vivo 
Clinical experience ex vivo 
Low immunogenicity 
Fairly long expression 
 
Insert limit 8 kb 
Low transfection efficiency in vivo 
Only proliferation targets 
Risk of insertional mutagenesis 
Manufacture extremely difficult 
Safety concerns for self-replicating 
particles 
Lentivirus Proliferating and non-
proliferating targets 
Insert limit 8 kb 
Safety concern for HIV related vectors 
No clinical experience 
Safety concerns for self-replicating 
particles 
Adeno-associated 
virus (AAV) 
Wide variety of targets in vivo 
Low immunogenicity 
Very long expression in vivo 
 
Insert limit 4.5 kb 
Immunogenicity for the host 
Risk of insertional mutagenesis 
Little clinical experience 
Manufacture very difficult 
Safety concerns for self-replicating 
particles 
Naked DNA Very low immunogenicity 
Manufacture easy and cheap 
Safe profile for the host 
Short duration of expression 
Very inefficient transfection in vivo and in 
vitro 
 
Transposons Proliferating and non-
proliferation targets 
Good safety profile regarding 
insertional mutagenesis 
Simple manufacture 
Requires transfection agents like 
electroporation that may affect cell 
viability 
mRNA 
electroporation 
Excellent for in vitro screening 
of transduced T cells 
Short duration of expression 
Cationic lipids Efficient transfection ex vivo 
Low immunogenicity 
Good safety profile 
Relatively simple manufacture 
Inefficient transfection in vivo 
Very short duration of expression 
Little clinical experience 
Condensed DNA 
particles 
Efficient transfection ex vivo 
Low immunogenicity 
Relatively simple manufacture 
Inefficient transfection in vivo 
Very short duration of expression 
No clinical experience 
 
 
Promote preferential pairing of exogenous TCR. In order to be functional the TCR 
heterodimer needs to have the same, or nearly the same, amount of TCR alpha and beta 
molecules inside the same cell. It is therefore desirable to use one vector encoding for 
both the alpha and beta TCR molecules. To ensure the same expression rate of these 
two molecules it would be better adding a picorna or vesicular stomatitis 2A peptide 
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between the two genes of interest instead of using two different promoters or an 
internal ribosome entry site (IRES). The virus-derived 2A linker peptide allows in fact 
the production of a single mRNA molecule encoding for the two genes with subsequent 
separation into two distinct proteins during translation. Several studies showed that the 
2A mediated cleavage is close to 100% efficiency (Szymczak, Workman et al. 2004) 
and it is better than IRES elements for TCR expression (Leisegang, Engels et al. 2008; 
Peng, Cohen et al. 2009). Additional improvement to the pairing of the exogenous TCR 
can be achieved by the introduction of a second cysteine bond in the constant region 
(Cohen, Li et al. 2007; Kuball, Dossett et al. 2007). Finally, it has been demonstrated 
by several studies that the partial or total murinization of the exogenous TCR ensures a 
better surface expression in addition to avoiding the mispairing problem with the 
human endogenous TCR (Cohen, Zhao et al. 2006; Sommermeyer, Neudorfer et al. 
2006; Voss, Kuball et al. 2006). Regarding the immunogenicity of murine TCRs, it has 
been demonstrated that patients treated with T cells expressing murine TCRs developed 
antibodies directed to the murine TCR variable region. However, this was not 
associated with the level of transduced cell persistence or with response to the therapy 
(Davis, Theoret et al. 2010). 
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6 AIMS 
In this thesis, the possibility of generating polyfunctional HCV-specific T cell 
responses was explored by studies on T cell redirection and vaccination. The specific 
aims for each study are presented here. 
 
 
Paper I:  
 
• To generate mouse T cell clones recognizing CTL target in HCV NS3 
• To characterize the functional avidity and affinity of the T cell clones 
• To identify the TCRs encoded by the T cell clones 
• To restore the new TCRs in human T cells by retroviral gene transfer 
 
 
Paper II: 
 
• To identify new TCRs that bind CTL target in NS5A (methods from paper I) 
• To restore the new NS5A TCRs and NS3 TCRs (from paper I) in human PBL  
• To test this approach with PBL from healthy donors and HCV patient  
• To evaluate and compare the functional profiles and antiviral activity of TCR-
redirected T cells against NS3 and NS5A  
 
Paper III:  
 
• To design new DNA vaccines based on the HCV NS5A immunogen used in 
paper II 
• To compare the immunogenicity of these vaccines in pre-clinical mouse models 
• To identify new T cell epitopes and evaluate functional profiles of vaccine-
induced T cells in the NS5A transgenic mouse model 
• To evaluate the efficiency of the vaccine-induced protection with tumor 
challenge in the NS5A transgenic mouse model  
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7 COMMENTS ON THE PAPERS’ MATERIAL AND 
METHODS 
This section is intended as a discussion on the methodology used in the hereby 
presented studies. The purpose is to explain the reason of choosing a particular method 
with advantages and limitations compared to other available techniques. 
 
 
7.1 DNA VACCINATION AND ELECTROPORATION (PAPER I, II AND III) 
The general aim of this thesis work was to explore the possibility to generate a specific 
and functional T cell immunity against HCV. The starting point of all the papers 
including in the thesis is the vaccination of mice (HLA-A2 transgenic in paper I and II 
and C57BL/6J wild-type and NS5A transgenic in paper III). In paper I and II, our goal 
was to generate CD8+ HCV-specific TCRs and due to the robust CTL responses 
previously observed with electroporation-enhanced DNA vaccination (Capone, 
Zampaglione et al. 2006; Ahlen, Soderholm et al. 2007), we therefore chose this 
approach here. The same applies to paper III for which the specific aim was to raise a 
functional immunity against HCV. In agreement with previous studies (Ahlen, 
Soderholm et al. 2007) our results show that a specific and effective CTL response 
against NS3 as well as NS5A could be generated by DNA vaccination followed by 
electroporation. The advantages of this approach over the DNA injection only are the 
higher DNA uptake and the immune-stimulation e.g. adjuvant effect caused by the 
electroporation itself by providing a local inflammation (Mathiesen 1999; Gronevik, 
von Steyern et al. 2005; Sallberg, Frelin et al. 2009).  
 
 
7.2 HUMAN CTL EPITOPES 
In paper I and II, the HCV CTL peptides used for evaluate the T cell reactivity were 
primarily the NS31073-1081 (gt1a CINGVCWTV and gt1b CVNGVCWTV) and 
NS5A1992-2000 (gt1a and gt1b VLTDFKTWL) sequences. Main reason for choosing 
these CTL epitopes is that these are HLA-A2–restricted CTL epitopes that have been 
associated with spontaneous clearance of acute HCV infection (Lechner, Wong et al. 
2000; Chang, Thimme et al. 2001; Urbani, Uggeri et al. 2001; Shoukry, Grakoui et al. 
2003). Other peptide variants for studies of genotypic cross-reactivity of the NS31073-
1081 epitope were also used (gt2 TISGVLWT, gt3 TIGGVMWTV, gt4 AVNGVMWTV 
and gt6 AINGVMWTV).  
 
 
7.3 HHD ANIMAL MODELS 
HLA-A2 transgenic mice, also called HHD mice (Pascolo, Bervas et al. 1997) were 
immunized to generate HCV-specific T cells. These mice have a human like MHC 
class I molecule so they can present human CTL epitopes like the one described in 
section 7.2. Therefore the purpose of using HHD mice was to obtain murine TCRs that 
are specific for human CTL epitopes. The advantage of having murine TCRs genes is 
mainly to avoid mispairing with the human endogenous TCRs (Cohen, Zhao et al. 
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2006; Sommermeyer, Neudorfer et al. 2006; Voss, Kuball et al. 2006). Regarding their 
use in clinical trials it was demonstrated that patients treated with T cells expressing 
murine TCRs developed antibodies directed to the murine TCR variable region, 
however this antibody response was not associated with the level of transduced cell 
persistence or response to the therapy (Davis, Theoret et al. 2010). 
 
 
7.4 HCV -SPECIFIC T CELL HYBRID CLONES (PAPER I AND II) 
HLA-A2 transgenic mice were immunized with NS3/4A or NS5A HCV DNA vaccine 
followed by electroporation. Purified CD8+ T cells from these mice were cultured with 
NS31073 and NS5A1992 peptides and fused with BW TCRneg cells (BW5147 alpha-beta-
cell line). This approach was chosen in order to immortalize the HCV-specific T cells 
for further cloning of the TCR genes from selected T cell hybrid clones. Selection was 
performed according to CD3 expression and to ability to secrete IL-2 and IFN-γ after 
stimulation with peptide loaded HHD spleenocytes (Pascolo, Bervas et al. 1997) and 
T2 cells. The advantages of using BW T cell hybrid clones rather than T cell clones 
relies on their easy culturing with no need for cytokines supplements in the medium, 
antigen restimulation or pre-activation. In addition, they can be used directly as reporter 
cells in our antigen presentation assays since they lack endogenous TCR. Therefore, 
this system represented a simple solution for the cloning of the TCR genes of our 
interest and at the same time allowed to characterize the TCR functionality for 
choosing the suitable TCR genes for redirection of effector cells. However, the main 
limitation is the lack of killing function because the CD8 molecule is not present in 
these hybridoma cells (Rock, Rothstein et al. 1990).  
 
 
7.5 CLONING OF TCR GENES (PAPER I AND II) 
To better understand the approach undertaken in our work, the next section will briefly 
describe the organization and rearrangement of αβ TCR genes. Here γδ TCRs will not 
be discussed since the hereby presented studies are exclusively focused on αβ TCRs. 
 
 
7.5.1 Germ-line organization and rearrangement of mouse TCR α and β 
chain genes  
The αβ TCR is composed of a heterodimer, which is designated the alpha (α) and beta 
(β) chain. Each chain is consisted of an extracellular variable (V) region and a constant 
(C) region as membrane-anchor. The genes encoding for the αβ TCR are expressed in 
cells of the T cell lineage only. Functional TCR genes are produced by rearrangements 
of the V and J (joining) segments in the α-chain and V, D and J in the β-chain. The α-
chain DNA undergoes a Vα-Jα joining and the β-chain undergoes two joinings: Dβ-Jβ 
first and then Vβ-DβJβ. Transcription of the rearranged genes gives the primary 
transcripts that are subsequently processed to give the mRNA finally encoding for the α 
and β chains. The leader sequence (L) is cleaved from the nascent polypeptide chain 
and is not present in the final protein. There is only one Cα chain and two Cβ chains 
that differ of a few amino acids only. 
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Figure 7. Example of gene rearrangement that leads to a functional αβ TCR protein 
heterodimer. Leader sequence (L); variable domain (V); constant domain (C); 
connecting sequence (H); transmembrane region (Tm); cytoplasmic tail (CT). 
 
For the murine TCR, there are up to 75 functional alpha-chain V gene  segments  (Tcra-
V) and around 50 for  the  beta-chain  (Tcrb-V) (Arden, Clark et al. 1995). According 
to the international ImMunoGeneTics (IMGT) information system 
(http://www.ebi.ac.uk), these genes can be grouped in 23 possible families for the 
alpha-chain V genes and 31 for the beta-chain. Each family can be identified using 
specific primers. Several mechanisms contribute during the gene rearrangement 
(combinatorial joining, alternative joining, junctional flexibility, nucleotide addition 
etc.) to a high degree of diversity among the TCRs e.g. up to 1018 individual different 
TCRs are theoretically possible to allow recognition of pathogens. The complementary 
determining regions (CDR) are responsible for the binding with the MHC-peptide 
complex. Crystallization studies showed that the CDR3 loops of the α and β chains 
bind the center of the peptide; the CDR1 loop from the α-chain binds the N-term of the 
peptide and the CDR1 loop from the β-chain binds the C-term of the peptide; the CDR2 
loops are in contact with the MHC molecule. The CDR3 loops of the α and β chains 
bind the center of the peptide, thus shows the highest degree of sequence variability. 
Most importantly, CDR3 is the main CDR responsible for recognizing the processed 
peptide antigen. 
 
 
7.5.2 Determining the protein coding sequences of the HCV TCRs 
In paper I and II, we used a multiplex PCR approach and a FACS-based antibody 
typing system with anti-Vβ specific antibodies to define the Vα and Vβ family usage 
of the identified HCV TCRs.  Oligoprimers specific for each of the TCR α and β 
chains could then be designed and used to retrieve the full-length coding sequence of 
each of our HCV TCR. Although this approach could appear laborious and time 
consuming, one must consider that our study had to deal with screening of hundreds of 
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T cell hybrid clones all specific for the HCV targets of interest. Other more direct and 
efficient approaches, as for example the “GeneRacer” (rapid amplification of cDNA 
ends), which is another way to retrieve TCR genes also exists as an alternative. 
However, this alternative is more reasonable when dealing with a few numbers of TCR 
candidates. 
 
 
7.6 TARGET CELLS WITH DIFFERENT HLA-A2 EXPRESSION LEVELS 
(PAPER I) 
The function of the MHC class I molecule is to expose self-peptides mainly generated 
from the degradation of cytosolic endogenous proteins via the proteasome. However, 
cross-presentation of foreign antigens may occur when the peptides come from 
exogenous proteins that entered the cell for example through phagocytosis. Generally, 
the small peptides produced by the proteasome are released into the cytosol and 
subsequently translocated to the ER where they bind the MHC class I molecule. The 
translocation of the peptides from the cytosol into the lumen of the ER occurs via the 
transporter associated with antigen processing (TAP) proteins. It is in the lumen where 
the MHC molecule is loaded with the peptide. Normally, healthy cells display self-
peptides originated during the cellular turnover, which do not activate CTLs due to 
central and peripheral tolerance mechanisms. But when a cell is infected by a virus and 
expresses viral proteins, the viral peptides will be loaded and displayed on the MHC 
class I molecule by which the infected cell could be recognize by the CTLs. It is for this 
reason that many viruses have developed immune escape strategies promoting down-
regulation of the class I MHC expression on cell surface. 
 
In our studies, we used as target cells the T2 cell line, which is commonly used as an 
antigen presenting cells. Being TAP deficient, the T2 cells allow easy loading of 
exogenous peptides on their MHC class I molecule. However one drawback of this cell 
model is that the density of the target molecules can be very high and thus is recognized 
by both high and low avidity TCRs. For this reason we also chose to test other target 
cell models such as the Huh-6 and C1R-A2 cell lines that have lower HLA-A2 
expression to study the recognition of target cells in a more physiologic condition. For 
the studies performed in paper I and II, the Huh-7 replicon cells (Figure 8) were also 
used as a target cells. Because the Huh-7/Lunet HCV replicon cells lacked HLA-A2 
expression (the endogenous HLA type are HLA-A11, -B54 and –B55 (Kurokohchi, 
Carrington et al. 1996; Jo, Aichele et al. 2009), these cells were engineered to express 
the HLA-A2 by lentiviral transduction as described by Jo et al (Jo, Aichele et al. 2009) 
that studied a genotype 2 HCV replicon. To better match our T cell epitopes we chose 
to use the HCV Con-1 strain (gt1b) replicon RNA. This model allows us to test the T 
cell recognition of endogenously processed NS31073 peptide coming from a subgenomic 
replicon expressing the HCV NS3-5 proteins. With this system there is a competition 
between the different endogenous peptides and, as a consequence, the amount of the 
NS31073 peptide presented on the HLA-A2 molecules is assumed to be lower. This 
model was also tested with the addition of exogenous NS31073 peptide. 
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Figure 8. Schematic representation of the different Huh7/Lunet cells that are used in 
this thesis. A) Huh7/Lunet HLAwt BLR neoET contain the HCV replicon and the 
HLA-A2 gene, thus they represent the real target; B) Huh7/Lunet BLR neoET only 
contain the replicon, thus they represent a control for the HLA-A2 specificity; C) 
Huh7/Lunet HLAwt BLR only contain the HLA-A2 gene, thus they represent a control 
for the specificity against the HCV epitopes. Modified from Jo et al (Jo, Aichele et al. 
2009). 
 
 
7.7 MHC-PEPTIDE PENTAMER ANALYSIS (PAPER I, II AND III)  
The MHC-peptide “pentamer” is a complex of five MHC molecules bound to a specific 
peptide and conjugated to a fluorocrome tag and it is primarily used to determine the 
frequency of antigen-specific T cells. Compared to traditional tetramers consisting of 
four MHC-peptide complexes that typically only allow one fluorescent label in the 
center of the complex, the pentamer has up to five fluorescent labels so it yields a 
brighter signal. Moreover MHC-peptide pentamers also have better avidity interactions 
with TCRs thus representing a sensible reagent for detection of antigen-specific T cells.  
In our studies, this technology was used for different purposes. In paper I, a NS31073-
specific HLA-A2 pentamer was used to evaluate differences in affinity to the MHC-
peptide complex within the different hybrid clones. The affinity of the TCR for the 
MHC-peptide complex is, in fact, usually quite weak compared for example to the 
antigen-antibody bond, (Kd from 10-4 to 10-7 M vs 10-6 to 10-10 M). However, the 
interaction between the T cell and the antigen presenting cell is strengthened by the 
presence of several accessory membrane molecules like CD8 or CD4, CD28, CD45R, 
CD86, ICAM-1 and LFA-8 and others (Oh, Hodge et al. 2003; Yang, Hodge et al. 
Huh7/Lunet HLAwt BLR neoET
HLA-A2EF1α BLR
Huh7/Lunet BLR neoET
EF1α BLR
Huh7/Lunet HLAwt BLRHLA-A2EF1α BLR
A
B
C
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2005). Since our T-BW hybrid clones lacked the CD8 and all the other molecules, we 
tested whether they could bind the NS31073-specific HLA-A2 pentamer. In paper II, 
NS31073- or NS5A1992-specific HLA-A2 pentamers were used to confirm the correct 
pairing and surface expression of the murine TCRs transferred into human cells. Only 
when both α and β chains were correctly expressed and assembled, we could see 
pentamer-positive cells comparable to the percentage of cells stained with the TCR-
specific Vβ antibody. In paper III we evaluated the frequency of NS5A-specific CD8+ 
T cells with a NS5A2251-specific H-2Kb pentamer for mouse T cells. In all the studies 
the MHC-peptide pentamer staining was always accompanied with one or several T 
cell markers to increase the validity of the assay. 
 
Variables to be considered when using antigen-specific pentamers are the following: 
variations of TCR density, differences in membrane lipid organization, state of T cell 
activation and differentiation status that can all affect the binding between the TCR and 
the pentamer. In view of this, one must take into account that the detected percentage of 
pentamer-positive cells could be an underestimation of the real number of antigen-
specific cells. Another point is that it has been observed a discrepancy between 
pentamer binding and CTL activity especially with IFN-γ ELISpot readout (Rubio-
Godoy, Dutoit et al. 2001).  
 
 
7.8 PHOENIX PACKAGING CELL SYSTEM AND RETROVIRAL 
TRANSDUCTION OF HUMAN PBL (PAPER I AND II) 
Retroviral vector-mediated gene transfer system was chosen to deliver the HCV TCR 
genes into T lymphocytes. We decided to use the retroviral system (the assembly of 
viral particles is represented in Figure 9) with a packaging cell line containing an 
amphotrophic envelope (Pizzato, Marlow et al. 1999) so that our recombinant particles 
could be made to target human T cells. Moreover, the flexibility of this system also 
allows us to easily package our TCR genes with other viral envelopes such as: 1) the 
VSV glycoprotein (VSV-G) (Frecha, Costa et al. 2008; Funke, Maisner et al. 2008) 
with tropism for all diving mammalian cells, or 2) the ecotrophic envelope of murine 
leukemia virus (MLV-E) (Albritton, Tseng et al. 1989) with tissue tropism for murine T 
cells. The retroviral vector chosen here is a MP71-PRE vector, that has the long 
terminal repeats (LTR) of the myeloproliferative sarcoma virus (MPSV) and an 
improved 5’ untranslated leader region, designed to mediate a higher transgene 
expression in human and murine T cells compared to the standard Mo-MLV-based 
vectors (Engels, Cam et al. 2003; Leisegang, Engels et al. 2008). 
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Figure 9. Phoenix packaging system (from Gary Nolan’s lab, Stanford University, CA, 
USA). The DNA plasmid pMP71 containing the TCR genes is transfected into the 
packaging cell line harboring the retroviral genes. The viral particles are assembled and 
the TCR gene is packaged into the capsids (thanks to the ψ sequence) inside the 
packaging cells. The recombinant viral particles are secreted in the culture medium and 
can be harvested and used to transduce the target cells. Modified from 
http://www.stanford.edu/group/nolan/tutorials/retpkg_7_phx_sys.html 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Viral particles production
LTR LTRTCR geneψ
RSV
LTR LTRTCR gene
CMV Env polyA
polyAGag-Pol CD8
LTR LTRTCR gene
DNA plasmid with the TCR genes
Transfection of packaging cell line
Transduction of  activated
T cells
ψ
 32 
8 RESULTS AND DISCUSSION  
Chronic HCV infection is one of the major causes of liver disease in the world. Despite 
that the introduction of new HCV-specific antiviral drugs in 2011, i.e. Telaprevir and 
Boceprevir, has increased the number of patients resolving the infection, not all 
infected individuals can be successfully cured (Jacobson, McHutchison et al. 2011; 
Poordad and Khungar 2011). In parallel, many vaccine candidates have been proposed 
but none of them is yet available in the clinic (Klade, Wedemeyer et al. 2008; 
Wedemeyer, Schuller et al. 2009; Eisenstein 2011; Habersetzer, Honnet et al. 2011; 
Torresi, Johnson et al. 2011). Several studies have tried to explain why some 
individuals clear the HCV infection while some others develop a chronic disease 
instead (Battegay, Fikes et al. 1995; Cerny, McHutchison et al. 1995; Rehermann, 
Chang et al. 1996; Cooper, Erickson et al. 1999; Gruner, Gerlach et al. 2000; Lechner, 
Wong et al. 2000; Chang, Thimme et al. 2001; Thimme, Oldach et al. 2001; Lauer, 
Ouchi et al. 2002; Thimme, Bukh et al. 2002; Wedemeyer, He et al. 2002; Lauer, 
Barnes et al. 2004; Cox, Mosbruger et al. 2005; Penna, Pilli et al. 2007). One of the 
current hypotheses is that acute resolving HCV infection is associated with a strong, 
broadly directed and sustained CD8+ T cell responses. However, a universal definition 
for the CD8+ T cell response in persistent HCV infection has not yet been agreed on 
(Neumann-Haefelin, Spangenberg et al. 2007). In general it seems that the HCV-
specific CD8+ T cell response is weaker or absent in the chronic patients and that both 
CD4+ and CD8+ T cells display functional impairments, including reduced 
cytotoxicity, reduced secretion of antiviral cytokines such as IFN-γ, and a reduced 
proliferative capacity (Urbani, Boni et al. 2002; Wedemeyer, He et al. 2002; 
Spangenberg, Viazov et al. 2005). Recently it has also been shown that an effective 
virus clearance is associated with polyfunctional HCV-specific CD4+ and CD8+ T 
cells (Ciuffreda, Comte et al. 2008). Polyfunctionality has been defined by the ability of 
both CD4+ and CD8+ T cells to produce cytokines such as IL-2 and IFN-γ and to 
proliferate (Iyasere, Tilton et al. 2003; Younes, Yassine-Diab et al. 2003; Zimmerli, 
Harari et al. 2005). The present thesis is focused on the generation of polyfunctional T 
cells against HCV and in the following paragraphs the results of each study are 
discussed. 
 
 
8.1 NOVEL HLA-A2 RESTRICTED MOUSE T-BW CELL HYBRID CLONES 
(PAPER I AND II) 
As discussed in section 7, we generated several HCV-specific T cell hybrid clones with 
different antigen specificity and avidity. The main advantage of this method is the 
relative simplicity of the culturing conditions for the hybrid clones compared to the T 
cell clones. The hybrid clones can be seen as a way to immortalize an antigen-specific 
T cell. Moreover, hybrid clones can either be used directly in immune recognition 
assays as reporter cells or be considered as a stable source of specific TCRs. In paper I, 
we generated and characterized four T cell hybrid clones (I8H4, I8A4, I4G7 and I4F8) 
specific for HCV NS31073. The first interesting finding was that our murine TCRs 
exhibit similar CDR3 motifs reported for human TCRs specific to the NS31073 peptide 
(Zhang, Liu et al. 2010), as the motifs ‘GG’ and ‘FGPGTR” observed in the human 
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NS31073 TCR were also commonly found in our mouse TCRs (Table 3). They also 
show a type 2 TCR bias (Turner, Doherty et al. 2006), which involves the frequent 
selection of “motifs” in the CDR3 loop of antigen-specific TCR Vα or Vβ chains and 
can be limited to the consistent selection of single or multiple amino acids at specific 
positions in the CDR3 region (Table 2 and 3). This suggests that highly conserved 
CDR3 motifs are shared by murine and human TCRs specific to the NS31073 peptide. 
Only few other studies have investigated the clonality of TCRs specific for HCV 
(Kashii, Shimizu et al. 1997; Umemura, Yoshizawa et al. 2000) even if it seems that 
there is a limited usage of TCR Vβ and clonal T cell expansion in the inflammatory 
sites of patients with autoimmune diseases (Davies, Martin et al. 1991; Gold and 
Bellgrau 1991; Hoshino, Nagata et al. 1997; Arenz, Meyer zum Buschenfelde et al. 
1998; Striebich, Falta et al. 1998; Yoshizawa, Ota et al. 1999). So it is possible to 
hypothesize a general mechanism by which a specific CDR3 motif corresponds to a 
certain antigen. This is reasonable if one thinks that given a certain HLA haplotype 
only few combinations of amino acids confer a stable binding between the TCR and the 
peptide-MHC complex. 
 
Table 2. CDR3α loops of the four NS31073-specific murine TCRs in this thesis and the 
human TCR reported by Zhang et al (Zhang, Liu et al. 2010). The mouse TCRs exhibit 
a type II pattern bias (Turner, Doherty et al. 2006) that is characterized by the 
preference of the motifs ‘KLTFG’. The same pattern has been found also in the 
CDR3α loops of the NS5A-specific murine TCRs as shown in summary Table S2. 
 
TCR clone (α  chain) V N J 
I8H4 CAMRE IT GNTGKLIFGLGTTLQVQP 
I8A4 CIVTD VE TGGYKAVFGSGTRLLVSP 
I4G7 CAVS RD TNTGKLTFGDGTVLTVKP 
I4F8 CAVS NM GYKLTFGTGTSLLVDP 
Human TCR (Zhang 2010) VYYCLVGA Y ILTGGGNKLT 
 
Table 3. CDR3β loops of the four NS31073-specific murine TCRs in this thesis and the 
human TCR reported by Zhang et al (Zhang, Liu et al. 2010). The motifs ‘GG’ and 
‘FGPGTR” in the human NS31073 TCR is also commonly found in the mouse TCRs. 
 
TCR clone (β  chain) V (N)D(N) J 
I8H4 CASSD ALGGED AEQFFGPGTRLTVL 
I8A4 CAS ASTGAS SYEQYFGPGTRLTVL 
I4G7 CASS 
CASS 
GGLGGH 
DYRD 
TLYFGAGTRLSVL 
SGNTLYFGEGSRLIVV 
I4F8 CASSQ EMGGA EQYFGPGTRLTVL 
Human TCR (Zhang 2010) VYFCASS TSGGAP ETQYFGPGTR 
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T-BW cell hybrid clones specific for HCV NS5A1992 were also generated with the same 
methodology described in paper I. After HAT selection 103 T-BW cell hybrid clones 
resulted CD3 positives, of these seven (named 18, 19, 37, 54, 57, 64 and 69) were also 
secreting IL-2 and/or IFN-γ after stimulation with peptide loaded T2. These seven 
clones were also tested on Huh-7/Lunet cells with and without loading of peptide and 
on T2 cells with two different peptide concentrations, the results are summarized in 
Table 4. Among the NS5A -specific T-BW cell hybrid clones the 19 and 69 were 
chosen as representatives of low (19) and high (69) affinity TCRs for further study of 
TCR redirection. 
 
Table 4. NS5A-specific T-BW cell hybrids and their reactivity against the NS5A1992 
CTL peptide. Fold increase in cytokine production after co-culture with hepatoma 
(Huh-7/Lunet) or T2 target cells loaded with or without the peptide (10µg/ml or 1 
µg/ml). 
 
Clone 
ID 
Cytokine Huh-7/Lunet 
(E:T 1:1) + 10 
µg/ml peptide 
Huh-7/Lunet 
(E:T 5:1) + 10 
µg/ml peptide 
T2  
(E:T 1:1) + 10 
µg/ml peptide 
T2 
 (E:T 1:1) + 1 
µg/ml peptide 
18 IL-2 0 1.5 1.5 0 
 IFN-γ 0 0 0 0 
19 IL-2 1.6 2.8 3.8 0 
 IFN-γ 0 0 1 0 
37 IL-2 0 0 1 0 
 IFN-γ 0 0 1 0 
54 IL-2 0 0 1 1.6 
 IFN-γ 0 0 0 0 
57 IL-2 2.7 5 6.7 2.9 
 IFN-γ 4.3 9.3 1 0 
64 IL-2 0 0 1.3 0 
 IFN-γ 0 0 1 0 
69 IL-2 1.6 2.8 11.4 5 
 IFN-γ 2.7 4.3 1.4 1 
 
 
8.2 AFFINITY TO NS31073/HLA-A2 PENTAMER (PAPER I) 
The concept of affinity in a molecular complex (like the one formed by the TCR and 
the pentamer) is intended as a specific type of equilibrium (usually defined by a 
dissociation constant) that measures the propensity of a larger object to separate 
(dissociate) reversibly into smaller components (Zhou, Rivas et al. 2008). In paper I, 
we report that, among the four clones tested for functionality, only I8H4 was able to 
bind the pentamer. This in our hands represented a further confirmation that this TCR 
clone could be considered as of high avidity for the peptide-MHC molecule. Even if it 
has been shown that a good effector functionality not necessarily associates with the 
pentamer binding (Burrows, Kienzle et al. 2000; Hernandez, Lee et al. 2000; Rubio-
Godoy, Dutoit et al. 2001; Lyons, Roszkowski et al. 2006; Laugel, van den Berg et al. 
2007) it is known that the total strength of the interaction between a T cell and its target 
cell is determined by several factors. These are the affinity of the single TCR for the 
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specific peptide-MHC complex, the number of these interactions and the contribution 
of accessory molecules (i.e. CD4 or CD8) binding to MHC molecules upon TCR 
engagement (Konig 2002).  One of the peculiarities of our hybrid clones, and 
accordingly to what has also been shown for other BW-T cell hybrid clones (Rock, 
Rothstein et al. 1990) is the lack of CD8 co-receptor suggesting that the I8H4 TCR 
must have a high avidity per se. The TCR avidity is very important in vivo as it seems 
to determine the T cell’s fate (Jameson, Hogquist et al. 1995; Saito 1998). According to 
Valitutti et al (Valitutti, Dessing et al. 1995) there is an interval of T cell functionality 
between a too high avidity threshold that impairs T cell activation by reducing the 
ability of the TCR to dissociate from the peptide-MHC complex and a too low limit 
where the T cells do not receive sufficient signal for activation. On the other hand 
several studies have shown the importance of high avidity TCRs especially for fighting 
viral infections (Neveu, Debeaupuis et al. 2008) because high avidity CTL clones lyse 
virus infected cells earlier and more rapidly than low avidity clones at any density of 
antigen complexes (Derby, Alexander-Miller et al. 2001). In Valitutti et al (Valitutti, 
Muller et al. 1996), it was shown that different effector functions are triggered by 
different thresholds of antigen density and in Wiedemann et al (Wiedemann, Depoil et 
al. 2006) that a relatively long lived immunological synapse is required to elicit a 
cytokine response in CD8+ T cells whereas a short lived synapse is sufficient to effect 
killing. In this context, the fact that the I8H4 clone has a capability of binding the 
pentamer in a CD8-independent manner makes it a promising candidate for subsequent 
studies of TCR transfer in human cells. 
 
 
8.3 COMPARISON OF THE FUNCTIONAL AVIDITY (PAPER I) 
Since only one of the four selected hybrid clones was able to bind the pentamer, we 
could not use the off rate of the pentamer as a measure to compare the functional 
avidity between the clones. Therefore in our study the functional avidity was defined as 
the reciprocal of the antigen concentration required to elicit the half-maximal effect 
response, measured as IL-2 secretion (EC50). Here we compared the IL-2 release of the 
hybrid clones after co-culturing with T2 cells loaded with diluted amounts of NS31073 
peptide and the result confirmed that I8A4 was a low avidity clone (400ng/ml EC50) 
while the other three could be considered as of moderate/high avidity (10ng/ml EC50). 
 
 
8.4 CROSS-GENOTYPE REACTIVITY (PAPER I) 
One of the most important features of a TCR is to be specific for its target. In our study 
we were interested in targeting exclusively the HCV NS31073 peptide. In order to test 
the TCR specificity in our hybrid clones, we therefore assessed their cross-reactivity to 
other viral peptides like the HCV NS31073 genotype 1b, 2, 3, 4, 5, 6, HCV NS52221, 
HCV NS5A1992, HCMV pp65495 and the Flu-NA231 peptide. This was particularly 
important for the Flu-NA231 peptide since cross-reactivity with HCV NS31073 genotype 
1b was previously reported (Wedemeyer, Mizukoshi et al. 2001). None of the hybrid 
clones showed cross-reactivity to the above peptides. In view of this, we concluded that 
all clones were of high specificity for the genotype 1 HCV NS31073. 
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8.5 RELEVANCE FOR HYBRID CLONE REACTIVITY OF EACH AMINO 
ACID POSITION IN THE NS31073 PEPTIDE (PAPER I) 
It has been proposed that one strategy of immune escape for HCV is to accumulate 
mutations within CTL epitopes to impair CTL recognition (Weiner, Erickson et al. 
1995; Erickson, Kimura et al. 2001; Grakoui, Shoukry et al. 2003; Meyer-Olson, 
Shoukry et al. 2004; Timm, Lauer et al. 2004). Despite this, some epitopes, like 
NS31073, show a very low variability (Chang, Rehermann et al. 1997; Seifert, Liermann 
et al. 2004).  The reason for this could be that mutations in this region would actually 
impair the viral fitness. In order to determine the key amino acid positions for the TCR 
and the MHC binding NS31073 alanine substitutes were generated and used for CTL 
stimulation. Results highlighted that position 2, 7 and 9 are important for the binding to 
the MHC molecule while positions 3, 4 and 5 are essential to the binding with the 
human TCR (Soderholm and Sallberg 2006). Interestingly in our study, we found that 
these positions do not have the same relevance in all the four murine TCRs. In 
particular we found that positions 3, 4, 5 and 7 are essential for all the four clones and 
this was expected since these are the positions essential for TCR binding, while 
position 2, 6, 8 and 9 are essential only for the low avidity clone I8A4. 
 
 
8.6 RECOGNITION OF HCV RNA REPLICON HEPATOMA CELLS 
(PAPER I) 
In paper I the T-BW cells hybrid clones were extensively tested on different targets. 
With these settings we were also able to verify whether the different target HLA-A2 
expression levels could further highlight the functional differences of the hybrid clones. 
The Huh-7/Lunet HCV replicon model added the possibility to evaluate the 
responsiveness of the clones to endogenously processed antigens. Taken together the 
results from this experiments confirmed that the T-BW cell hybrid clones had different 
levels of functional avidity. In particular the I8H4 clone showed the highest avidity 
being the only one able to recognize the Huh-7/Lunet HCV replicon cells not loaded 
with exogenous peptide. In view of this, the I8H4 and I4F8 clones were chosen as the 
best candidates for the subsequent study on TCR redirection. 
 
 
8.7 TRANSFER OF TCR GENES INTO HUMAN T CELLS (PAPER I AND II) 
As previously mentioned, for clearing infectious diseases, particular attention needs to 
be given to high avidity CTLs. In this respect, an emerging therapeutic approach is the 
adoptive cell therapy with the use of redirected T cells (Duval, Schmidt et al. 2006; 
Rosenberg, Dudley et al. 2008; Al-Khami, Mehrotra et al. 2011). In our study, we 
selected the TCRs with the highest avidity for the NS31073 peptide (H4 and F8 
described in paper I) and for the NS5A1992 peptide (19 and 69 described in paper II) and 
we progressed to the TCR transfer in human T cells with the retroviral vector discussed 
in paper I and with the packaging system described in section 7.8. Briefly, the four 
TCR full-length gene pairs were codon-optimized for expression in human cells, cloned 
into a retroviral vector with a F2A autoprotease sequence in between the β-chain and 
α-chain. Recombinant viral particles were produced and activated human PBL were 
transduced by spinoculation (Zhang, Liu et al. 2010). The four murine TCRs all have 
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different Vβ usage (F8: Vβ 4, Η4:  Vβ 8.3, 69:  Vβ 8.1−8.2, 19: Vβ 6), therefore we 
could use specific Vβ antibodies as markers of transgene expression in human cells. 
We first transduced PBL from healthy donors and tested the surface expression of the 
murine TCRs together with their correct αβ pairing by staining with HLA-A2 NS31073 
and NS5A1992-specific pentamers (as discussed in section 7.7). The transduction 
efficiency was 10-20% of CD3+ cells with an equal distribution on CD8+ and CD8- 
cells. We then assayed the peptide sensitivity on peptide-loaded T2 cells and found that 
NS5A TCR-transduced human T cells, as also shown by the parental T-BW cells 
hybrid clones, had a lower functional avidity compared to the high avidity NS3 TCR F8 
and H4. With the perspective of a potential therapeutic approach, we also transduced 
PBL from chronic HCV patients to verify whether the TCR functionality could be 
restored in their T cells. Moreover our findings demonstrated that all four TCRs were 
correctly assembled and expressed on the cell surface by the MHC-pentamer staining. 
 
 
8.8 GENERATION OF ANTIGEN-SPECIFIC POLYFUNCTIONAL T CELLS 
BY TCR REDIRECTION (PAPER II) 
Polyfunctionality has emerged as an important T cell feature that is associated with an 
efficient immune response against several pathogens like HIV (Betts, Nason et al. 
2006; Duvall, Precopio et al. 2008) and tuberculosis (Caccamo, Guggino et al. 2010);  
therefore it is desired also as result of vaccination (Aagaard, Hoang et al. 2009; 
Burgers, Riou et al. 2009; Abel, Tameris et al. 2010; Derrick, Yabe et al. 2011; Lang 
Kuhs, Ginsberg et al. 2012; Tan, Eriksson et al. 2012). In order to be defined as 
polyfunctional, a T cell (CD8+ or CD4+) must show at least two functions including 
degranulation, secretion of cytokines or chemokines (Seder, Darrah et al. 2008). To 
identify a protective immune response it is important that the antigen-specific T cell 
population secrete at the same time IFN-γ, IL-2 and TNF-α. Studies about 
mycobacterium tuberculosis have shown that IFN-γ has a central role in clearing the 
infection (Flynn, Chan et al. 1993) but it is not sufficient for protection alone (Elias, 
Akuffo et al. 2005). The combination of IFN-γ and TNF-α instead leaded to enhanced 
killing of another parasite like Leishmania major (Bogdan, Moll et al. 1990; Liew, Li et 
al. 1990). On the other hand IL-2 is essential, since it promotes T cells expansion and 
can also improve the CD8+ T cell memory capacity and effector functions (Williams, 
Holmes et al. 2006). Therefore in paper II, we analyzed the production of these three 
cytokines in the different TCR-redirected T cells by intracellular cytokine staining. In 
addition, we tested the CD107a upregulation after peptide stimulation and investigated 
the cytolytic activity on T2 and Huh-7/Lunet replicon target cells. 
 
 
8.8.1 Multi-cytokine production 
The ability of transduced cells from healthy donors and chronic HCV patients to 
produce TNF-α, IL-2 and IFN-γ after stimulation with NS31073 or NS5A1992 peptide-
loaded T2 cells was assessed in paper II. Interestingly, we found a clear difference in 
the number of cytokines secreted between NS3- and NS5A-redirected T cells. In 
particular, T cells expressing the NS3-specific TCRs H4 and F8 had up to 50% of triple 
and double secreting populations while the other 50% was positive for only one 
cytokine. On the other hand, the T cells expressing the NS5A-specific TCRs 19 and 69 
had up to 60-80% of single-cytokine secreting cells (preferentially IFN-γ). . Similar 
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results were found in both CD8+ and CD8- populations. In Figure 10 differences in 
functional quality of CD8+ and CD8- TCR redirected T cells from chronic HCV 
patients are presented. 
 
 
F8             H4              19              69
CD8+
CD8-
Number of 
functions
1
2
3
 
 
Figure 10. Differences in functional quality in TCR redirected T cells from chronic 
HCV patients. CD8+ and CD8- redirected T cells were assessed for the ability to 
secrete TNF-α, IL-2 and IFN-γ after stimulation with NS31073 or NS5A1992 peptide-
loaded T2.  
 
 
This result is in line with the finding from a study on T cells redirected against renal 
cell carcinoma (RCC) cells (Leisegang, Turqueti-Neves et al. 2010). In that study, TCR 
from a tumor infiltrating lymphocyte, called TIL53, was isolated from a RCC (from a 
HLA-A2 positive patient) and cloned into the MP71-PRE retroviral vector. The 
constant chains of the TCR were substituted with murine constant chains and codon 
optimized. Human PBL from healthy donors and RCC patients retrovirally transduced 
with this TCR showed a multifunctional profile as demonstrated here for both our NS3-
TCRs.  
 
 
8.8.2 Recognition and elimination of Huh-7/Lunet replicon cells 
The Huh-7/Lunet replicon cells used in this assay were engineered to express the firefly 
luciferase reporter protein. The advantage of this model is that since the firefly 
luciferase expression is controlled by the HCV replicase activity, the viral replication 
activity can be studied by the bioluminescence imaging system (IVIS Spectrum) using 
a high dimensional CCD-camera. In view of this, our approach was to culture the Huh-
7/Lunet together with the redirected T cells and measure the intensity of 
bioluminescence. Our findings pointed out that NS3-specific redirected T cells could 
reduce the bioluminescence intensity of the Huh-7/Lunet replicon cells in a dose 
dependent manner (up to 0.01:1 E:T ratio for the H4 TCR). On the other hand, the 
NS5A TCR-redirected cells were less effective even if a partial reduction of 
bioluminescence could still be observed. With the same settings, we tested the 
production of IFN-γ and TNF-α and we found that H4 and F8 TCRs expressing cells 
were able to produce INF-γ and to some extent TNF-α while the 19 and 69 TCRs 
expressing cells only produced IFN-γ.  This result is in accordance with the finding of 
Jo et al (Jo, Aichele et al. 2009), in which the antiviral mechanisms of HCV NS5B2594 -
   39 
specific CTLs were tested using a HCV genotype 2 replicon cell system. This elegant 
study also demonstrated that a strong inhibition of HCV replication (up to 95%) can be 
observed also at low E:T ratios (up to 1:100) and it is mainly due to the action of IFN-γ. 
 
 
8.8.3 CD107a surface mobilization 
Surface staining of the CD107a molecule (also called LAMP-1) after stimulation with 
specific targets allows quantification of the recent lytic activity (Sabouri, Usuku et al. 
2008). For our redirected T cells, we compared the CD107a mobilization after co-
culturing with peptide-loaded T2 and Huh-7/Lunet replicon cells. We found that after 
the co-culture with peptide loaded T2 cells, both NS3- as well as NS5A TCRs 
transduced samples had an increase in CD107a surface mobilization while co-culturing 
with Huh-7/Lunet replicon cells caused CD107a up-regulation in the NS3 TCR-
transduced T cells only. This result was particularly interesting since it may indicate 
that different target cells stimulate different effector functions in our redirected T cells. 
Our hypothesis is that the difference in antigen specificity between the TCR redirected 
cells reflects also a different degree of cytotoxic potential. We thus continued to 
examine whether the TCR-transduced cells had different effect on the Huh-7/Lunet 
replicon cells in terms of hepatocellular injury. 
 
 
8.8.4 NS3- and NS5A TCR-redirected T cells differ in their hepatotoxic 
potentials  
Huh-7/Lunet replicon cells were co-cultured with the TCR redirected T cells at ratio 
1:1 and a kinetic analysis of the AST released in the supernatants was performed. These 
data were combined with the quantification of luciferase protein and with the counts 
and the morphology observation of the Huh-7/Lunet replicon cells from the same co-
culture. All together these results showed a significant difference between the NS3 and 
NS5A TCR-redirected T cells in terms of cytotoxic activity, e.g. the NS3-specific 
effector cells are prone to induce cytolysis of Huh-7/Lunet target cells whilst the 
NS5A-specific cells seem to favor a non-cytotoxic mechanism to reduce the 
bioluminescence of the Huh-7/Lunet target cells.  These findings support the 
observations that the non-cytolytic mechanism contributes to control HCV infection 
(Lohmann, Korner et al. 1999; Blight, Kolykhalov et al. 2000) and in particular IFN-γ 
is the main inhibitor of viral replication (Frese, Schwarzle et al. 2002); HCV-specific 
CD8+ T cells indeed can inhibit viral replication acting both in a direct cytolytic 
manner and through cytokine secretion without direct cell-to-cell contact (Liu, Zhu et 
al. 2003; Jo, Aichele et al. 2009). Moreover in vivo studies conducted with 
chimpanzees showed that viral clearance can occur in the absence of elevated alanine 
aminotransferase levels and with only minimal evidence of liver cell injury but with 
detectable IFN-γ messenger RNA in the liver (Bigger, Brasky et al. 2001; Su, Pezacki 
et al. 2002; Thimme, Bukh et al. 2002). Since the main target of HCV is the liver, an 
elimination of infected cells through a cytolytic manner could actually be comparable 
or even worse than the viral persistence in terms of liver injury. Therefore, CTL that 
uses an alternative effector mechanism that does not require killing of virus-infected 
cells might be more desirable. In the light of a possible therapeutic use of NS5A 
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redirected T cells it is important to consider that the non-lytic activity could be an 
advantage for those chronically HCV infected patients who already suffer from a 
severe liver damage. This approach would be intended as a complement to the antiviral 
therapy. Moreover, the combined effect of NS3- and NS5A-redirected T cells still 
needs to be evaluated in vivo. 
 
 
8.9 GENERATION OF NS5A-SPECIFIC IMMUNE RESPONSE BY 
VACCINATION (PAPER III) 
From the studies on TCR redirection, it has emerged that NS3- and NS5A-specific T 
cells are qualitatively different for many functional aspects. In particular, the NS5A-
specific TCRs seem to confer an antiviral property without being cytotoxic. This could 
be considered as a positive aspect as HCV infected patients need to clear the infection 
but cannot stand a massive liver damage. Therefore the next study was focused on the 
characterization of the immune responses of the NS5A DNA vaccination. In this study, 
the immunogenicity of different domains of HCV NS5A was characterized in details in 
wild-type C57BL/6J mice as well in immunologically tolerant HCV NS5A-transgenic 
(Tg) mice. 
 
 
8.9.1 Importance of NS5A domains in priming immune response 
NS5A is an essential protein in the HCV replication machinery (Blight, Kolykhalov et 
al. 2000; Tellinghuisen, Marcotrigiano et al. 2005) and it has been proposed as a target 
for antiviral therapy (Coelmont, Hanoulle et al. 2010; Nettles, Gao et al. 2011; Lawitz, 
Gruener et al. 2012). Noticeably, it has been shown that the combined treatment of 
DAAs against NS3 and NS5A could obtain a sustained virological response even 
without the addition of interferon-alpha and ribavirin (Lok, Gardiner et al. 2012). In 
this study we utilized a series of DNA constructs consisting of the full-length and 
truncated versions of NS5A (Table 5) to characterize the vaccine properties of this 
protein. 
 
Table 5. NS5A-based DNA expression plasmids used for immunogenicity evaluation. 
 
Construct Aminoacids in NS5A 
1 (WT NS5A) 1-449 (full length) 
2 1-163 
3 1-215 
4 1-326 
5 1-378 
6 31-449 
7 105-449 
8 211-449 
9 302-449 
coNS5A 1-449 (full length codon 
optimized) 
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The humoral immune response was first evaluated after DNA or protein vaccination in 
groups of C57BL/6J (H-2b) mice. By analyzing the NS5-specific IgG titers, it was 
found that the carboxyterminal domains II and III of NS5A are most important for 
priming NS5A-specific humoral immune responses, which is in line with that several 
human B cell epitopes have been found in the carboxyterminal region of NS5A 
(Khudyakov Yu, Khudyakova et al. 1995; Rodriguez-Lopez, Riezu-Boj et al. 1999). 
 
 
8.9.2 Identification of CTL epitopes and comparison of cellular immune 
response in wild-type and NS5A-Tg mice 
Several MHC class I epitopes for NS5A are described in other mouse haplotypes, but to 
our knowledge none is described for H-2b. Therefore, our primary goal here was to 
define these epitopes to be able to evaluate the cellular immune response to NS5A after 
DNA immunization. Briefly, the sequence of 87 synthetic 20-mer peptides (15 aa 
overlap) spanning the full-length NS5A gt1b gene and class I epitopes was predicted 
using the SYFPEITHI database version 1.0 (Rammensee, Bachmann et al. 1999). The 
peptides were synthetized and tested for stabilization of surface MHC class I expression 
on the RMA-S cell line. Two peptides able to bind the MHC class I molecule with high 
affinity were identified. In order to verify whether these two peptides corresponded to 
the in vivo processed CTL epitopes, we immunized wild-type and NS5A-Tg mice and 
further analyzed the specific immune response by IL-2 and IFN-γ ELISpot assay and 
51Cr release assay using peptide-loaded RMA-S cells. The results confirmed that the 
two peptides identified were able to induce IL-2 and IFN-γ in wild-type mice and IFN-
γ even if to a low extent, in NS5A-Tg mice. Thus, the NS5A-Tg animals had a partially 
impaired T cell response to NS5A. On the other hand, the 51Cr release assay pointed out 
that there was no difference in lytic activity between wild-type and transgenic mice. 
However, this could be explained by the five days in vitro peptide re-stimulation of 
spleenocytes from immunized mice. On the other hand the NS5A-Tg mice did had a 
significantly lower number of NS5A specific CD8+ T cells compared to the wild-type 
mice when direct ex-vivo quantification was performed.  The reason why we decided to 
investigate also the immune response in NS5A-Tg mice is that these are 
immunologically tolerized to the NS5A antigen and may better mimic the immune 
responses in chronic HCV patients. Here, tolerance is defined as the process by which 
the immune system does not react to a certain antigen. This could be a self-antigen or 
an external antigen. Despite in our transgenic mice the NS5A is an external antigen, its 
constant expression in the organism made it less reactogenic for the immune system. 
 
 
8.9.3 In vivo protection against growth of NS5A-expressing tumor cells 
To evaluate CTL functionality in vivo we developed a challenge model using syngeneic 
tumor cells (EL-4 lymphoma cells) expressing the NS5A-protein. Mice were 
challenged after vaccination to assess the protection efficacy against tumor growth 
(Encke, zu Putlitz et al. 1998; Frelin, Alheim et al. 2003). Mice were given one 
injection of the full-length constructs of NS5A, wild-type or codon optimized, and 
challenged with NS5A-EL-4. Interesting, only the mice immunized with the codon 
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optimized NS5A received an immunological boost by the tumor cells that express 
NS5A. This could be explained by the fact that the codon optimized version of NS5A 
primes stronger NS5A-specific immune response compared to the wild-type version.  
Our result also revealed that region aa 216 to 449 was important for protection against 
NS5A-EL-4 tumour growth. Moreover we tested tumor protection in mice vaccinated 
with the constructs containing truncated versions of NS5A and found that the one with 
intact CTL epitopes was mainly the one being able to raise a protective immune 
response against tumor growth, suggesting that the tumor protection observed is 
dependent on presence of intact CTL epitopes. Interestingly, even though the construct 
9 lacks the CTL epitopes it was able to provide a tumor protection, and indicates that 
the protection may not only dependent on the two identified CTL epitopes.  
Importantly, our results suggest that the minimum region of NS5A needed to mediate 
protection against tumor growth and activate NS5A-specific T cell responses is the 
region connecting domain I and II, and the amino-terminal part of domain III. 
Interestingly, protection against tumor growth in immunized NS5A-Tg mice was 
present but was partial. This demonstrates that even in a tolerogenic environment, a T 
cell response can be activated by NS5A-DNA immunization and mediate tumor 
protection to some extent. 
 
 
8.9.4 Expansion and polyfunctionality of activated NS5A-specific T 
cells. 
The polyfunctionality of NS5A-specific T cells was evaluated after vaccination in wild-
type and NS5A-transgenic mice. These two groups showed similar patterns of 
polycytokine secreting cells (IFN-γ, IL-2, TNF-α). Moreover, they showed similar 
levels of CD107a expression despite the NS5A-Tg group presented lower levels. The 
results suggest that NS5A-DNA immunization is an efficient method to generate a 
specific polyfunctional T cell response. This is particularly important because of the 
protective potential of this vaccine. In a study by Darrah et al (Darrah, Patel et al. 2007) 
a mouse model for Leismania major infection was used to demonstrate that protective 
vaccines were able to induce polyfunctional CD4+ T cells (secreting IFN-γ, IL-2, TNF-
α) while non-protective vaccines induced only mono or double- cytokines secreting T 
cells. In our study we indeed demonstrated that NS5A DNA vaccination induces an 
antigen-specific polyfunctional T cell response in vaccinated wild-type and to some 
extent NS5A transgenic mice, which also protect from growth of HCV NS5A+ tumor 
cells. 
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9 CONCLUDING REMARKS 
The hereby presented studies were focused on the discovery of new ways to improve 
the immunological response to a panel of HCV epitopes, which are of particular 
importance as having been identified in patients who cleared the infection. With this 
strategy, we were able to generate a polyfunctional antigen-specific T cell response 
using a TCR redirection approach and DNA vaccination. 
 
In paper I, we generated four T-BW cell hybrid clones specific for HCV NS31073 with 
different grades of TCR avidity, in particular I8H4, I4G7 and I4F8 are considered as 
high avidity while I8A4 showed to be a low avidity clone instead. Redirect T cells 
expressing TCR genes from two of the high avidity clones (H4 and F8) were 
polyfunctional with a clear antiviral property against human hepatoma HCV replicon 
cells. 
 
Paper II was focused on the comparison between TCR redirected T cells specific for 
NS31073 and NS5A1992 peptides. In this study, only high avidity TCRs were chosen for 
genetic transfer. The most interesting finding was on the correlation between the 
antigen specificity and the antiviral activity. We demonstrated that while NS3 -specific 
T cells present a polyfunctional profile with a clear lytic activity against human 
hepatoma HCV replicon cells, NS5A-specific T cells mainly secrete IFN-γ and 
interfere with viral replication albeit in a less effective manner but could spare the 
target HCV+ hepatoma cells from cytolysis.  
 
In paper III, we evaluated the immune response against HCV NS5A after vaccination.  
In particular, and accordingly to the previously identified B cell epitopes (Khudyakov 
Yu, Khudyakova et al. 1995) we discovered that the C-terminus is a target for the 
humoral response. For what concerns the cellular response, we first identified two 
MHC class I epitopes restricted for H-2Kb and H-2Db and then used them to evaluate 
the T cell response after DNA immunization in wild-type and NS5A-Tg mice. The 
interesting finding was that the NS5A-specific immune response could be raised in 
both wild-type and transgenic mice even though the second group showed evidences of 
tolerance (with lower levels of cytokine production after immunization). The two 
groups of mouse strains were also challenged with tumor cells expressing NS5A after 
vaccination and an effective protection against tumor growth was found. Taken 
together these results highlight the validity of NS5A DNA vaccination in generating a 
polyfunctional T cell response even in a tolerized mouse model and therefore this 
vaccine could be considered as a therapeutic candidate to assist in the treatment of 
HCV infection. 
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10 FUTURE PERSPECTIVES 
The present thesis was proposed to investigate the possibility to generate polyfunctional 
effector T cells to eliminate HCV-infected cells. Our results suggest that this can be 
achieved; polyfunctional T cells directed against different HCV CTL targets can either 
be engineered in vitro by TCR gene transfer or raised in vivo by vaccination. Such 
effector T cells are capable to eliminate HCV RNA replication or prevent tumor growth 
in an antigen-specific manner. The result is encouraging since polyfunctional T cells 
are considered as correlates of protective antiviral immunity in chronic virus infections 
including HCV (Harari, Dutoit et al. 2006; Ahmed and Gottschalk 2009). However, 
much still remains to be explored and further investigated to make sure the approach 
taken here are fully effective against HCV. The next step would be to further explore 
these approaches to investigate their potentials in vivo to cure HCV infection.  The 
TCR-reagents may also serve as tools to gain better understanding of HCV 
immunology. How this could be further carried out is discussed in this section. 
 
 
10.1 TCR-REDIRECTED CELLS AS IMMUNE THERAPY 
Despite having an impressive potential in the therapy of cancer and infectious diseases, 
TCR-redirected T cells may also have harmful potentials. First of all, the genetic 
manipulation itself, especially when delivered by integrating vectors could potentially 
lead to oncogenic transformation. The second concern is autoimmune reactivity e.g. 
when the chosen antigen is expressed in normal cells and tissues, or when a mispaired 
TCR becomes auto-reactive. Some of these concerns have in part already been 
addressed in our studies: for example, the use of mouse TCR is one way to circumvent 
mispairing with endogenous human TCR chains. Further improvement would be to use 
a non-integrating vector to decrease the risk of oncogenic transformation. Potential 
autoimmune reactivity usually applies to non-virus related tumor cells, in which the 
antigen also is expressed in normal tissue. An example is “vitiligo” caused by T cell 
immunotherapy of melanoma (Dudley, Wunderlich et al. 2002; Yee, Thompson et al. 
2002). In view of this, it would be sensible to be able to shut down the TCR-expression 
or eliminating the transferred cells upon any signs of severe side effects.  In this regard, 
administration of T cell-specific antibodies or corticosteroids to block autoimmune 
reactions would be useful. A more specific approach is the introduction of the herpes 
simplex virus thymidine kinase (HSV-TK) in the adoptive transferred T cells (Bonini, 
Ferrari et al. 1997; Tiberghien, Ferrand et al. 2001). However, the immunogenicity of 
HSV-TK, resulting in elimination of transferred gene-modified T cells, could be an 
issue (Riddell, Elliott et al. 1996; Berger, Flowers et al. 2006). Co-transduction of the T 
cells with the CD20 gene for possible depletion using the CD20-specific antibody 
Rituximab (Introna, Barbui et al. 2000; van Meerten, Claessen et al. 2006) is also 
possible; however, obvious side effect in this case, is the elimination of the patient’s B 
cells, which is not always desirable. An interesting new approach is the TCR editing of 
human T cells to completely shut off endogenous TCR expression (Provasi, Genovese 
et al. 2012). This technique has also been used to generate clinical-grade T cells 
genetically modified ex vivo to express a chimeric antigen receptor (CAR) to redirect 
the specificity to a tumor-associated antigen (Torikai, Reik et al. 2012). A future 
scenario for the adoptive cell therapy would be to have access to TCR-edited cell lines 
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specific for different HCV antigens that could be used directly in the clinic without the 
need for personalized ex-vivo modification. 
 
Current knowledge is that T cells exist in several distinct stages of differentiation. 
While T cells are defined as naïve before encountering the antigen, they will develop 
into effector memory (TEM) and long-lived central memory (TCM) after activation. The 
latter phenotype of T cells is found to be responsible for immune surveillance and 
tumor eradication in vivo (Monteiro, Batliwalla et al. 1996; Van den Hove, Van Gool et 
al. 1998; Sallusto, Lenig et al. 1999; Barber, Wherry et al. 2003; Klebanoff, Gattinoni 
et al. 2005). Although the mechanism behind this has not been fully elucidated, several 
hypotheses have been proposed (Fearon, Manders et al. 2001; Kaech and Ahmed 2001; 
Sallusto, Geginat et al. 2004). One interesting model about T cell differentiation has 
been proposed by Seder et al (Seder, Darrah et al. 2008). According to this model T cell 
differentiation is a process where, following antigen stimulation, T cells progressively 
gain functionality until they reach the best polyfunctional effector status as TCM and are 
able to secrete IL-2, IFN-γ and TNF-α. Prolonged antigen stimulation results in 
progressive loss of multiple cytokines secretion as well as memory potential. In Figure 
10 the models for effector and memory T cell differentiation are represented.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Models for effector and memory differentiation of CD4+ (A) and CD8+ (B) 
T cells. Antigen stimulation leads to the differentiation process by which the T cells 
gain progressively functionality until the best effector polyfunctional phenotype able to 
secrete IL-2, IFN-γ and TNF-α. Prolonged antigen stimulation results in progressive 
loss of multiple cytokines secretion as well as memory potential and eventually 
terminal differentiation and cell death. For CD8+ T cells two possible mechanisms for 
the generation of TCM and TEM are represented: linear differentiation (green dotted 
lines) and fixed lineage (red dotted lines) (Kaech and Wherry 2007). Modified from 
Seder et al (Seder, Darrah et al. 2008). 
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Taking in consideration the polyfunctional profile of TCM cells it would be reasonable 
to use them as preferential recipient cells for our HCV TCRs to further increase their 
antiviral efficiency. 
 
 
10.2 HOW TO TARGET THE LIVER 
Being the main site of viral replication, the liver environment has mostly a suppressive 
effect on HCV-specific T cells. In our studies, we discussed how to generate an 
efficient immune response against HCV and how to direct this response to the liver to 
efficiently clear the virus in loco. Data obtained with transgenic mice expressing HCV 
antigens in the liver have demonstrated that vaccine-induced T cells can have ability to 
home to the liver and attack specifically the cells expressing HCV proteins (Ahlen, 
Soderholm et al. 2007). Studies conducted with influenza A virus also demonstrated 
that intranasal infection was highly efficient in inducing cytotoxic and functional CD8+ 
T cell responses in the liver (Keating, Yue et al. 2007; Polakos, Klein et al. 2007). 
Intranasal adenovirus infection also seems to be better than subcutaneous infection in 
inducing a functional CTL response in the liver. Therefore, the route of inoculation 
seems to have an importance for T cell priming (Lukens, Dolina et al. 2009), thus can 
have an implication in vaccination against HCV. Another interesting finding regarding 
the T cell homing to the liver is the discovery that the a higher level of CD161 
molecule is expressed on HCV- and HBV-specific CD8+ T cells compared to CD8+ T 
cells specific for non-hepatotropic viruses (Northfield, Kasprowicz et al. 2008). 
Interestingly, the CD8+ T cells can be divided into three subpopulations depending on 
the CD161 staining profile: CD161-, CD161+ and CD161+++ (Takahashi, Dejbakhsh-
Jones et al. 2006; Northfield, Kasprowicz et al. 2008; Billerbeck, Kang et al. 2010). 
The CD161+++ subpopulation in particular has an unconventional phenotype, which 
also reflects a unique functional profile (Klenerman and Thimme 2012). This 
subpopulation expresses CCR6 and CXCR6, which allow homing to the liver even 
under non-inflammatory conditions. CD161+ and CD161- CD8+ T cells home instead 
to the liver only under inflammatory conditions via other chemokine signals. A 
functional characteristic of these CD8+CD161+++ T cells is the ability to secrete IL-17 
and IL-22, alone or in combination with IFN-γ and TNF-α (Klenerman and Thimme 
2012). IL-17 may induce upregulation of other proinflammatory chemokines and 
cytokines on several cell types including hepatocytes, therefore in these settings, its 
function may be promoting inflammation and cellular recruitment (Tesmer, Lundy et 
al. 2008). IL-22 seems instead to have a crucial hepatoprotective role in murine models 
via antiapoptotic and pro-proliferative effects on hepatocytes (Wolk and Sabat 2006; 
Zenewicz, Yancopoulos et al. 2007). This newly identified T cell subset has thus 
interesting potential. A possibility in this sense may be for example the genetic 
modification of redirected T cells to allow different levels of CD161 expression and 
further evaluate their ability to specifically home to the liver. 
 
 
10.3 THERAPEUTIC VACCINATION 
Ideally, a therapeutic vaccine should be able to cure a chronic patient by inducing an 
endogenous immune repertoire in persons who are already infected. Since HCV 
genotype 1 virus is the most difficult to treat and the most common HCV genotype 
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worldwide, the effort toward a genotype 1 therapeutic vaccine, as presented in paper 
III, is thus justified. However, due to the high HCV mutation rate and the presence of 
several quasi-species, it would be sensible to develop one or more cocktails of drugs or 
genotype-specific vaccines. Moreover, the availability of a reliable animal model to test 
HCV vaccine candidates would definitely improve the results in this research area. 
Recently, the generation of a transgenic mouse model described by Dorner et al 
(Dorner, Horwitz et al. 2011) has opened new possibilities in this field and would be 
interesting to explore. Another aspect that must be taken into account is that the liver 
environment does not represent the best place for T cell priming so a vaccine that is 
able to efficiently prime the T cells outside this organ may have a better chance to 
induce an effective immune response. However the ability of the polyfunctional T cells 
generated after NS5A DNA immunization to migrate into the liver and clear HCV 
antigen expressing cells still remains to be investigated. 
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